




Contents lists available at ScienceDirect

Neuroscience Letters

journal homepage: www.elsevier.com/locate/neulet



Review

Mechanisms of distal axonal degeneration in peripheral neuropathies

Christopher R. Cashman^{a,b}, Ahmet Höke^{a,*}

^a Departments of Neuroscience and Neurology, USA

^b MSTP- MD/PhD Program, Johns Hopkins University, Baltimore, MD 21205, USA

ARTICLE INFO

Article history:

Received 27 October 2014

Received in revised form 16 January 2015

Accepted 19 January 2015

Available online xxx

Keywords:

Peripheral neuropathy

Guillain–Barré syndrome

Diabetes

HIV neuropathy

Mitochondrial aging

Campylobacter jejuni

Chemotherapy induced peripheral neuropathy

Wld^S

Mechanisms of neuropathy

Post-infectious neuropathy

ABSTRACT

Peripheral neuropathy is a common complication of a variety of diseases and treatments, including diabetes, cancer chemotherapy, and infectious causes (HIV, hepatitis C, and *Campylobacter jejuni*). Despite the fundamental difference between these insults, peripheral neuropathy develops as a combination of just six primary mechanisms: altered metabolism, covalent modification, altered organelle function and reactive oxygen species formation, altered intracellular and inflammatory signaling, slowed axonal transport, and altered ion channel dynamics and expression. All of these pathways converge to lead to axon dysfunction and symptoms of neuropathy. The detailed mechanisms of axon degeneration itself have begun to be elucidated with studies of animal models with altered degeneration kinetics, including the slowed Wallerian degeneration (Wld^S) and Sarm knockout animal models. These studies have shown axonal degeneration to occur through a programmed pathway of injury signaling and cytoskeletal degradation. Insights into the common disease insults that converge on the axonal degeneration pathway promise to facilitate the development of therapeutics that may be effective against other mechanisms of neurodegeneration.

© 2015 Elsevier Ireland Ltd. All rights reserved.

Contents

1. Introduction	00
1.1. Clinical overview of selected diseases	00
1.1.1. Diabetic neuropathy	00
1.1.2. Chemotherapy induced peripheral neurotoxicity	00
1.1.3. Human immunodeficiency virus neuropathy	00
1.1.4. Non-HIV infectious causes: hepatitis C and <i>Campylobacter jejuni</i>	00
2. Mechanisms of peripheral neuropathy	00
2.1. Metabolic dysregulation	00
2.2. Covalent modification	00
2.3. Organelle damage and reactive oxygen species	00
2.3.1. Impaired mitochondria function	00
2.3.2. Endoplasmic reticulum dysfunction	00
2.3.3. Reactive oxygen and nitrogen species	00
2.4. Intracellular and inflammatory signaling	00
2.5. Axonal transport defects	00
2.6. Channelopathy	00

Abbreviations: AGE, advanced glycation end products; AIDP, acute inflammatory demyelinating polyradiculoneuropathy; AMAN, acute motor axonal neuropathy; CIDP, chemotherapy induced peripheral neurotoxicity; ddC, 2',3'-dideoxycytidine; ETC, electron transport chain; G6P, glucose-6-phosphate; G6PD, glucose-6-phosphate dehydrogenase; GBS, Guillain–Barré syndrome; HCV, hepatitis C virus; IGF-1, insulin-like growth factor-1; IFN- α/γ , interferon α or γ ; MPTP, mitochondrial permeability transition pore; Nmnat, nicotinamide mononucleotide adenylyltransferase; PARP, poly(ADP-ribose) polymerase; RAGE, receptor of advanced glycation end products; RNS, reactive nitrogen species; ROS, reactive oxygen species; TLR, toll-like receptor; Ube4b, ubiquitination factor E4B; Wld^S, slowed Wallerian degeneration gene.

* Corresponding author at: Department of Neurology, Johns Hopkins University School of Medicine, 855 North Wolfe St., Rangos 248, Baltimore, MD 21205, USA.

Tel.: +1 410 955 2227.

E-mail address: ahoke@jhmi.edu (A. Höke).

<http://dx.doi.org/10.1016/j.neulet.2015.01.048>

0304-3940/© 2015 Elsevier Ireland Ltd. All rights reserved.

3.	New insights into mechanisms of degeneration	00
4.	Conclusion	00
	Acknowledgements	00
	References	00

1. Introduction

Peripheral nerve degeneration is a common disorder of the nervous system whereby sensory and/or motor axons no longer effectively communicate between the periphery and central nervous system. The prevalence of peripheral neuropathy in the United States has been reported to be nearly 15% in adults over the age forty [108].

Peripheral neuropathy is not a single, homogenous disease, but is instead a mix of different clinical presentations, natural histories, and pathologies. Patients may present with motor insufficiency (weakness), sensory abnormalities (numbness, paresthesias, hyperalgesia/allodynia, pain), autonomic symptoms, or a combination of all, often depending on the particular disease. These various constellations of neurological symptoms suggest motor, sensory, and autonomic axons have differing susceptibilities to various disease processes. Additionally, while most neuropathies are chronic, slowly progressive conditions, some neuropathies have a more acute onset and gradual recovery [111] (reviewed in [140,275,293]). The heterogeneity of peripheral neuropathies is likely secondary to the initiating event. Few neuropathies are present in isolation, but, rather, are often secondary to other systemic illnesses, including diabetes and infectious causes such as human immunodeficiency virus and hepatitis C virus. Additionally, peripheral neuropathies may be iatrogenic, arising from the toxicity of drugs given as part of antiretroviral or chemotherapy regimens.

Despite the great variety of cause and symptoms, the pathophysiology of peripheral neuropathies is limited to only a handful of mechanisms. In this article, the pathophysiological mechanisms of various types of peripheral neuropathy – diabetic neuropathy, chemotherapy induced peripheral neurotoxicity (CIPN), HIV- and non-HIV infectious neuropathies – will briefly be reviewed in an effort to examine how many different disease process converge onto a handful of cellular targets involved in the axonal degradation pathway to produce peripheral nerve dysfunction. As it is among the most heavily studied, diabetic neuropathy will serve as the prototypical example for many of the mechanisms, then additional detail added for particular diseases.

1.1. Clinical overview of selected diseases

1.1.1. Diabetic neuropathy

Diabetes mellitus is a very common chronic disease. In 2014, over 9% of the United States population (21 million people) has been diagnosed with diabetes [47], and the prevalence is expected to increase [220]. Diabetes is the most common cause of peripheral neuropathy, accounting for over half of the cases in a recent Dutch study [207].

Diabetic peripheral neuropathy is classically a sensory neuropathy presenting as numbness and paresthesias in a length dependent “stocking glove” distribution, whereby the feet are affected earlier and more severely than the hands (as reviewed in [51]), but painful, autonomic, or motor neuropathies may also occur (reviewed in [249]). In two studies of patients with type-I diabetes, intense glucose control reduced the risk of peripheral neuropathy by 60% [102,110]. This finding suggests that the elevated glucose levels in the body may be pathogenic. While hyperglycemia may be a large component of the pathogenesis of diabetic neuropathy, non- hyperglycemic effects of diabetes, including reduced trophic

support (hypoinsulinemia in type I and advanced type II diabetes) and mitochondrial health and function, may also be important.

1.1.2. Chemotherapy induced peripheral neurotoxicity

While improved cancer treatment regimes and higher rates of remission are a boon to modern medicine and cancer biologists, many of the commonly used anti-neoplastics have long term toxic effects that currently are not well mitigated during treatment [45]. Indeed, chemotherapy induced peripheral neurotoxicity (CIPN) has increased in incidence as cancer remission rates continue to climb due to improved cancer therapies (as reviewed in [12,45]). While the incidence and prevalence of CIPN varies by agent, in general, 30–80% of treated patients develop a peripheral neuropathy (as reviewed in [96]). Patients experience motor and sensory symptoms, including numbness, pain, and weakness [248], so severely that they may be dose-limiting. The wide variety of symptoms suggests chemotherapeutic agents may harm multiple types of neurons, as well as different parts of neurons, including the axon (axonopathy) or the soma/ganglion (ganglionopathy) (as reviewed in [118]). The most common causes of CIPN include taxanes, such as paclitaxel, platinum agents including cisplatin and oxaloplatin, and proteasome inhibitors such as bortezomib and will, thus, be the focus of discussion. For other compounds, readers are referred to Argyriou et al's excellent, recent review [12]. Within a pharmacological class, there is also heterogeneity. For example, cisplatin has chiefly chronic effects, but oxaliplatin has toxic neurological effects in both the acute and chronic setting, suggesting different processes may underlie early and late pathology. Thus, the particular pathophysiology of CIPN depends not only on the family of chemotherapeutic but also on the specific member of the family.

1.1.3. Human immunodeficiency virus neuropathy

The global prevalence of the human immunodeficiency virus (HIV) in 2009 was found to be 33.3 million [1], and nervous system defects, including a peripheral neuropathy, is common in the disease [159,229]. Interestingly, while control of the virus has improved over the past few decades, the incidence of neuropathy has increased from 13% in 1993 to 42% in 2006 [229]. This increase in prevalence during the era of effective treatments suggests that the neuropathy is not caused by the virus alone, but also by the drugs used to treat it [87]. HIV neuropathy is chiefly a sensory neuropathy of pain, paresthesias, and absent ankle reflexes [67]. Direct viral infection of neurons or Schwann cells has not been well demonstrated, but the virus has been recovered from some nerve samples [52,74]. Viral concentration in these samples is remarkably low, suggesting viral particles and proteins must enter the nerve through other cells, such as macrophages or T-cells. Indeed, careful studies of viral tropism have shown that particles recovered from nerve are consistent with macrophage and T-cell infectious particles, [127] and that viral proteins colocalize with macrophages in vivo [115]. These findings suggest the virus is brought to the nerve by immune cells, but does not directly infect neuronal cells [66,115]. The viral proteins gp120 and protein R (VPR) are especially important toward the observed neurotoxicity. The primary mechanisms of the neuropathy appear to be immune damage from viral proteins and mitochondrial toxicity from the antiretrovirals (as reviewed in [131,133]).

1.1.4. Non-HIV infectious causes: hepatitis C and *Campylobacter jejuni*

In addition to HIV, hepatitis C virus (HCV) and *C. jejuni* infection are also associated with peripheral neuropathy. Hepatitis C is a viral infection that may become an intractable, chronic infection, best known for causing liver cirrhosis and hepatocellular carcinoma. In 2011, the best estimate of prevalence was 2.35% of the world population (160 million people), making it five times more common than HIV [143]. HCV has long been known to be associated with neurological complications including peripheral neuropathy and encephalopathy [241]. A study in France of 321 patients with hepatitis C infection found 9% and 10% develop a sensory or motor neuropathy, respectively [40]. HCV-associated peripheral neuropathy has been further divided into four subtypes based on distribution: polyneuropathy, mononeuritis multiplex, cranial neuropathy, and a combination of polyneuropathy/cranial neuropathy, with axonal degeneration and demyelination on biopsy [180]. Importantly, the hepatitis C virus has not been shown to replicate or infect muscle or nerves directly [14], so, as was the case with HIV, neuropathy must develop through indirect, inflammatory mechanisms instead of direct viral infection.

In these studies of HCV and peripheral neuropathy, cryoglobulinemia was found to alter the complication profile associated with HCV infection [40] and be associated with more widespread neuropathy [180]. Cryoglobulins are immunoglobulins that reversibly aggregate at cooler (less than 37 °C) temperatures and are associated with a variety of chronic and autoimmune diseases, with HCV infection being one of the best characterized (as reviewed in [95]). Between 30 [213] and 78% [180] of patients with HCV have been reported to have cryoglobulinemia. Although the presence of cryoglobulinemia as a risk factor for neuropathy has been debated, it is interesting to consider Nemni, et al's findings that, while cryoglobulinemia may not increase the severity of neuropathy, it changes the profile to one of a more generalized syndrome [180]. This observation is pertinent since cryoglobulinemia is known to lead to systemic vasculitis, suggesting ischemic injury and inflammation may be important for the development and/or advancement of HCV induced peripheral neuropathy [14].

The bacteria *C. jejuni* is a common cause of gastroenteritis and is associated [100] with a post-infectious neuropathy in 1 of 1000 infections [5]. First described by Guillian, Barré, and Strohl [111], the neuropathy often occurs a week after infection and is classically an acute, ascending, motor neuropathy (as reviewed in [275]). With an estimated incidence of 1/100,000 [5], Guillian–Barré syndrome (GBS) is somewhat rare but may cause permanent disability or be fatal secondary to diaphragmatic paralysis and respiratory failure [275]. While some viruses may also cause GBS, *C. jejuni* is believed to cause 30% of all cases [5]. GBS has recently been appreciated to have multiple subtypes [275], including acute inflammatory demyelinating polyradiculoneuropathy (AIDP) and acute motor axonal neuropathy (AMAN) [109,119,162]. The pathophysiology of AMAN is more thoroughly understood than AIDP, and, thus will be used to discuss principles that may be generalized to other subtypes.

2. Mechanisms of peripheral neuropathy

2.1. Metabolic dysregulation

In diabetes, hyperglycemia leads to dysregulation of the polyol, hexosamine, and pentose phosphate pathways that ultimately leads to reactive intermediates that damage the axon and Schwann cells. Glucose-6-phosphate (G6P) can be diverted by the enzyme glucose-6-phosphate dehydrogenase (G6PD) from glycolysis into the anaerobic pentose phosphate pathway to produce more NADPH. When intracellular glucose (and, thus, glucose-6-phosphate) levels are very high, G6PD is inhibited [300], and

glucose is instead diverted into the polyol pathway by the enzyme aldose reductase to produce the alcohol sorbitol (see Fig. 1). Sorbitol and other polyols accumulate in various tissues throughout the body, including the sciatic nerve of experimental rat models [101]. Sorbitol reduces the level of membrane component myo-inositol in cultured neuroblastoma cells exposed to high levels of glucose by inhibiting its cellular import [290]. This disruption of the axonal membrane could reduce the ability of the axon to propagate an action potential [290] or impair the ability to regenerate following injury since a “wave” of lipogenesis is necessary for regeneration [156], and nerves from patients with diabetes demonstrate areas of focal demyelination and remyelination, a lipid intensive process [245]. Additionally, myo-inositol depletion in a rat model of type II diabetes is associated with reduced Na⁺-K⁺-ATPase activity, leading to a nerve conduction deficits [107].

NADPH is one of the primary intracellular antioxidants, so its depletion reduces the ability of a cell to protect against oxidant damage, ultimately leading to apoptosis. The polyol pathway also depletes NADPH, since it is used in the conversion of glucose into sorbitol (see Fig. 1). The pentose phosphate pathway is an anaerobic metabolic pathway used to create NADPH reducing equivalents and other biomolecules. G6PD is the gateway to this pathway, so its inhibition by high glucose levels is a second hit against the production of antioxidants, ultimately leading to increased rates of apoptosis [247,300]. Thus, dysregulation of the polyol pathway by hyperglycemia may cause nerve damage through multiple mechanisms: membrane damage by reduced levels of myoinositol, and increased radical damage from a reduced antioxidant capacity.

2.2. Covalent modification

In addition to the potential toxicity from alternative metabolic pathways in diabetes, glucose itself can be toxic as a result of non-enzymatic addition of glucose to proteins via the Amadori product [6] of the Maillard reaction [155] whereby glucose condenses with the amine group of amino acids to form modified proteins, “advanced glycation end products” (AGEs), as reviewed in [35]. AGEs have been observed in both the axons and Schwann cells of peripheral nerves, with enrichment of AGEs in samples from patients and animal models of diabetes [261,234,84]. These molecules work through direct modification of biomolecules.

Among the modified proteins is collagen, which leads to increased thickness [240], immune complex deposition [36], and LDL trapping in vitro [37] in comparison to non-modified collagen. All of these are characteristics of an atherosclerotic plaque, which can lead to luminal narrowing of a vessel and greater risk of occlusion, thereby reducing blood flow and exposing the nerve to hypoxic conditions. This hypoxic risk is increased by AGEs that quench the vasodilator nitric oxide released from endothelial cells [38], demonstrating how multiple aspects of the response to hyperglycemic synergize to damage tissue.

One of the principal components of the basement membrane, laminin is critical for the health and development of neurons and Schwann cells (as reviewed in [62]) and is directly modified by AGEs. Modified laminin inhibits neurite outgrowth in vitro when compared to nonmodified laminin [90], and this reduction in outgrowth persists despite neurotrophin stimulation or preconditioning [84]. One can imagine the AGE modifications of collagen and laminin combining to produce recurrent injury to axons: the modified collagen facilitates hypoxic conditions which damages the axon, but the modified laminin is not permissive to axon regrowth, thereby limiting peripheral nerve recovery and producing an axonopathy.

Glyceraldehyde-3-phosphate, a metabolic intermediate of the polyol and glycolytic pathway, can nonenzymatically bind to, and,




Fig. 1. Summary of metabolic pathways. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

A variety of metabolic processes that branch off of glycolysis are dysregulated in diabetes, including the polyol, pentose phosphate, and hexosamine pathways. This dysregulation leads to protein modification, changes in extra- and intra-cellular signaling (effectors in blue text), and decreased antioxidant capacity secondary to reduced NADPH levels (shown in green). Red arrow indicates inhibition of the pentose phosphate pathway by elevated glucose levels.

thus interfere with, other proteins [42] (as reviewed in [246]). Glyceraldehyde-3-phosphate may also activate the protein kinase C (PKC) pathway, since it can be degraded into diacylglycerol, one of the secondary messengers of the canonical PKC signaling cascade [203]. This pathway has been shown to be particularly relevant for vascular complications associated with diabetes (as reviewed in [73]).

The hexosamine pathway produces glucosamine-6-phosphate and glutamate from fructose-6-phosphate and glutamine (see Fig. 1). Glucosamine-6-phosphate is ultimately converted into UDP-N-acetylglucosamine (UDP-GlcNAc) and other hexosamines to serve as substrates for glycoprotein sugar moieties (reviewed in [39]). UDP-GlcNAc can be covalently bound to proteins by O-GlcNAc transferase. These modifications are believed to regulate protein function by competing with kinase phosphorylation [63]. Indeed, O-GlcNAcylation has been observed on numerous proteins regulating transcription, including RNA polymerase II [63], Sp-1 [287], and insulin receptor substrates 1 and 2 (IRS1/2) [89]. In the case of Sp-1, O-GlcNAcylation leads to increased expression of more pathogenic proteins such as TGF β [81]. Thus, over activity of the hexosamine biosynthetic pathway modifies the activity of numerous transcription factors, ultimately leading to gross changes in cell state and signaling.

In addition to proteins, other biomolecules, such as DNA, can also be modified by AGE products. Plasmid DNA incubated with reactive AGE products produced double strand DNA breaks and base modifications [174]. A small study of 31 type II diabetic patients in Turkey found higher AGE DNA adduct concentration in patients with diabetes compared to controls, despite the use of

oral hypoglycemic drugs [198]. This study confirms the ability of AGE compounds to react with other biomolecules *in vivo* as well as illustrates how modified molecules remain in the tissue despite initiation of hypoglycemic therapy, although it remains unclear what effect the modified DNA has in these tissues.

DNA modification is also believed to be one of the mechanisms responsible for the chronic symptoms of CIPN, particularly following treatment with platinum containing compounds like cisplatin and oxaliplatin. Incubation of DRG neurons *in vitro* with oxaliplatin and cisplatin decreases neurite outgrowth, increases platinum/DNA adducts [160,238], and apoptosis-mediated cell death [238]. The exact mechanisms of toxicity is platinum adduct formation with nuclear and mitochondrial DNA [160,197] which initiates apoptosis [161]. Interestingly, the increased accumulation of platinum/DNA adducts is selective for DRG neurons, over cancer cells, *in vitro* [160], likely due to expression of a selective organic cation transporter [231]. This pattern may explain the particular vulnerability of sensory neurons to platinum compounds like cisplatin and oxaliplatin.

2.3. Organelle damage and reactive oxygen species

Mitochondria, the site of oxidative phosphorylation, are intrinsically linked to the development of reactive oxygen species (as reviewed in [175]). Damage or pathology associated with these organelles may lead to cell death through apoptosis or energetic failure, thereby increasing sensitivity to ischemia. Given the constant flux of electrons and oxygen in mitochondria, it is not surprising that they are likely the primary site (more than 90%)

of reactive oxygen species production (as reviewed in [19]). Mitochondrial dysfunction, both in its normal function and increased ROS production, has been implicated in the pathogenesis of many different neuropathies.

In addition to mitochondria, (dys) function of the endoplasmic reticulum also facilitates development of neuropathy. As a fundamental component of the protein synthesis and modification pathway, insults that may inhibit the proteasome or increase the concentration of unfolded proteins may trigger stress, thereby releasing calcium and initiating the unfolded protein response, leading to cell death through multiple pathways (as reviewed in [282]). Impairment in both the endoplasmic reticulum and mitochondria are a common mechanism to all of the pathologies discussed.

2.3.1. Impaired mitochondria function

While it is perhaps expected that mitochondria, as the primary energy production site for the mammalian cell, would display certain pathology in the setting of a hyperglycemia and aberrant metabolism, recent work has suggested that the mitochondria play a much more active role in the development of neuropathy through cell death and injury.

In a murine model of type II diabetes, Vincent et al., found abnormal mitochondrial morphology in sensory neurons despite an increased mitochondrial density in their axons, neurites, and cell bodies compared to healthy control mice [86,255]. Vincent et al., suggest increased mitochondrial fission is necessary to meet the greater energetic requirements of a hyperglycemic state, but too rapid mitogenesis leads to unhealthy mitochondria [255]. Alternatively, mitochondria fission may represent a response to toxicity. In a 2005 review, Youle and Karbowski proposed a model of the induction of apoptosis whereby the machinery necessary for fission also mediates apoptosis [145,291].

Mitochondrial dysfunction is also evident with an impaired respiratory capacity. Indeed, in an animal model of type I diabetes, mitochondria in sensory neurons displayed depressed respiratory function compared to control animals due to lower activity of complex I and IV secondary to reduced protein expression of certain complex components [56]. The reduced protein levels, in turn, are likely due to reduced PGC-1 α /AMPK axis signaling that occurs in the setting of hyperglycemia and metabolic derangement [55]. Impaired electron transport chain function also causes an increase in ROS generation (as reviewed in [177]), which will be discussed in more detail later.

Mitochondrial dysfunction is a major mechanism of CIPN across all of the various chemotherapeutic agents. The taxane family of chemotherapeutics, including paclitaxel, exercises its antineoplastic effects through inhibition of tubulin depolymerization (as reviewed in [128]), thereby interfering with the stable/labile balance of microtubules [128], including the axons of neurons [17]. Swollen and vacuolated mitochondria are commonly observed in the axons of sensory nerves of animal models CIPN caused by paclitaxel [98,279,280]. By interfering with microtubule dynamics, paclitaxel has been shown to interfere with calcium signaling in mitochondria and the endoplasmic reticulum by the opening of the mitochondrial membrane permeability pore, leading to calcium triggered calcium release from the ER [135,171]. The opening of the mitochondrial permeability transition pore (MPTP) also leads to release of ROS and cytochrome C [252]. For these reasons, the MPTP has been hypothesized to be a major, convergent effector of axonal degeneration [21] via induction of apoptosis [205] and downstream calcium activated effectors. The increase in calcium may also facilitate cellular injury by activating the calcium dependent protease calpain. Indeed, paclitaxel treated animals that were also administered a calpain inhibitor displayed improved neurological scores and fewer signs of sensory axon degeneration, even

though apoptotic rates were unaffected [270]. Furthermore, calpain also degrades the neuronal calcium sensor-1 protein, leading to reduced IP₃ signaling [27,28]. In addition to direct toxic and apoptotic effects, the abnormal mitochondria may also be pathogenic because of reduced respiratory ability, thereby contributing to energetic failure [280,301].

Mitochondrial dysfunction has also been observed in axons following CIPN caused by oxaliplatin and bortezomib [279,301]. Commonly used for multiple myeloma, bortezomib is a chemotherapeutic that inhibits the proteasome. Like platinum agents and taxanes, it is well known to cause painful sensory neuropathy in humans and animals [166]. Bortezomib, like paclitaxel, has been shown to lead to mitochondrial calcium release leading to activation of the apoptotic cascade [142] and energetic collapse [302].

In HIV neuropathy, both the virus and the drugs used to treat the infection lead to mitochondrial dysfunction. When cultured DRG neurons were exposed to HIV infected macrophages, mitochondrial membrane potential in the soma decreased as reactive oxygen species formation increased, but there was no effect on neurite mitochondria, suggesting there are distinct mechanisms of injury between the soma and axon [115]. This separation has been well characterized in studies on inflammatory and apoptotic signaling (discussed below).

In addition to induction of apoptosis and increased calcium from the MPTP (as reviewed in [206]), mitochondria are functionally impaired because of damaged DNA. In a recent study of sural nerve mitochondria in HIV patients with and without sensory neuropathy, mitochondrial deletions were more common in those with neuropathy [144], with more mutations observed in distal mitochondria versus those in more proximal aspects [144]. These mutations were correlated with reduced mitochondrial respiratory function [144]. Interestingly, mitochondrial defects were not observed in the proximal sciatic nerve, only the sural nerve, which suggests the distal aspect of specific types of axons are more sensitive to toxicity [144]. Lehman et al.'s study of mitochondrial mutations and dysfunction lead to the development of a novel, unifying theory of neuropathy based on mitochondrial aging and, thus, distal axon susceptibility. Mitochondria must travel from the soma to the periphery, which may take months to years. During this process, mitogenesis takes place, but in an imperfect manner, leading to an accumulation of mitochondrial DNA (mtDNA) mutations, and, thus deficits. This process would make the distal most aspect of an axon more susceptible to further injury than the proximal aspect, mirroring the length dependency of many neuropathies. Additionally, Lehman et al., also suggested that the higher density of mitochondria in small, lightly or non-myelinated fibers [144] will make these fibers especially sensitive to mitochondrial dysfunction, as is observed with the primarily sensory component of many neuropathies. Lastly, one can imagine that processes that affect axonal transport will only exacerbate mitochondrial dysfunction distally since it takes longer to reach distal points. This hypothesis of mitochondrial aging is an exciting development toward a unifying explanation of many different peripheral neuropathies, but more testing is needed, especially toward the development of therapeutics that protect mitochondria from chronic damage and aging. This hypothesis suggests that agents that directly damage mitochondrial DNA may exacerbate neuropathic symptoms, and this is indeed what is observed in the treatment of HIV infection.

Mitochondrial dysfunction in HIV neuropathy occurs through a variety of antiretroviral treatments (as reviewed in [71]). Treatment of rabbits with a nucleoside analog (2',3'-dideoxycytidine; ddC) show robust dysmyelination, abnormal Schwann cell morphology, and slowing of nerve conduction velocity [9,91]. Treated patients display an increased density of swollen, vacuolated mitochondria with inclusions in the axons and Schwann cells of the sural nerves in those treated with ddC [72]. These abnormal mitochon-

dria correlate with a reduced level of mtDNA [72], likely as a result of inhibition of mtDNA polymerase [158] (as reviewed in [130,131]) and subsequently reduced protein levels [144]. This reduced amount of mtDNA may exacerbate the mtDNA damage from aging as described in the hypothesis above. Indeed, the ratio of mtDNA to nuclear DNA in nerve samples is reduced with infection and drug over infection only, and marginally recovers upon drug cessation [68]. Like HIV itself, the antiretroviral-induced damage to mtDNA also leads to impaired mitochondria function.

Antiretrovirals are sufficient to interfere with mitochondrial function. By inhibiting replication of the mitochondrial genome, a number of the necessary components of the electron transport chain may not be produced, thereby leading to uncoupled transport and decreased oxidative phosphorylation, as is observed in neuronal mitochondria treated with ddC in vitro [132]. Interestingly, patients on nucleoside analogs often display hyperlactemia, which resolves upon drug cessation. One could imagine systemic mitochondrial inhibition would lead to decreased oxidative phosphorylation, and, thus a concomitant increase in glycolysis and lactic acid fermentation. Thus, antiretroviral drugs and HIV infection synergize to cause greater injury [305]. As with other neuropathies, mitochondrial dysfunction may cause additional cellular injury through the production of reactive radical species, as outlined below.

2.3.2. Endoplasmic reticulum dysfunction

The endoplasmic reticulum (ER) is also vulnerable to various toxicities, as evidenced by the induction of the unfolded protein response. While ER inhibition in diabetes is not well characterized, bortezomib has been shown to induce a transient stress response in the Schwann cell ER, leading to myelination deficiency and an increased cytokine expression [224]. This off target effect is perhaps unsurprising, given bortezomib's mechanism of action as a proteasome inhibitor one would expect the unfolded protein response to increase, as well.

While most of the work has examined mitochondrial dysfunction in the setting of HIV neuropathy and anti-retroviral therapy, the ER may also be adversely affected by viral proteins. Indeed, in a study by Höke, et al., the HIV envelope protein gp120 induced ER calcium release by binding to the chemokine receptor to activate the canonical IP₃ signaling cascade leading to rapid increase of intracellular calcium [123]. When calcium storage in the ER was experimentally reduced, the neurons were more resistant to gp120 triggered cell death, reinforcing the important role of the ER in mediating degeneration [123]. A similar calcium response has been described upon DRG neuron exposure in vitro to Vpr [2]. While the downstream effect of the increased calcium has not been well studied, one could imagine a similar mechanism to what is observed in CIPN with calpain protease activation and the induction of apoptosis (as reviewed in [116]).

2.3.3. Reactive oxygen and nitrogen species

The electron transport chain (ETC) produces superoxide as a byproduct of electron uncoupling followed by reduction of oxygen to form the free radical [20], but mitochondria also produce hydrogen peroxide, hydroxide radicals, and nitric oxide, all of which are reactive species that can directly damage other proteins or DNA through covalent modification (as reviewed in [177,227]). While superoxide production is a common feature of all eukaryotic cells, the nervous system may be particularly vulnerable to free radical damage because of large energetic demands and high lipid content (as reviewed in [168]).

Natural antioxidants help mitigate this damage, such that the depletion of these molecules increases the susceptibility of the cell the oxidative damage. Uncoupling proteins serve to reduce the electrochemical potential across the mitochondrial inner mem-

brane by bypassing ATP synthase, thereby uncoupling the hydrogen ion gradient from the generation of ATP (as reviewed in [208,228]). ROS generation may be reduced by uncoupling since the electron transport chain (ETC) complexes that may generate superoxide radical are bypassed (as reviewed in [173,228]). The uncoupling protein (UCP) family includes three proteins, UCP-1, UCP-2, and UCP-3, which are all hydrogen ion channels or transporters. UCP-1 was identified to be involved in thermogenesis from brown fat [181], while UCP-2 and UCP-3 were found [85] to be important for homeostasis [99] and thermogenesis [31] in a variety of tissues including white adipose tissue and brain for UCP-2 [99] and DRG, brown adipose tissue, and skeletal muscle for UCP-3 [257,284]. UCP-2 and UCP-3 were also quickly identified as inhibitors of ROS generation in the mitochondria [179,253], since null mice displayed evidence of increased ROS production and damage (as reviewed in [30]). UCPs are also critical for the attenuation of damage from ROS secondary to hyperglycemia. A variety of studies have shown all three UCP family members to protect cells from hyperglycemia induced ROS generation when the proteins are overexpressed [209,257]. Interestingly, in the setting of hyperglycemia, UCP-3 expression is actually reduced [257]. These data suggest development of damage secondary to hyperglycemia may be facilitated by a reduction of UCPs in vivo, or, alternatively, loss of UCPs in vivo may facilitate the development of diabetic complications. This relationship makes UCP expression an enticing therapeutic target, but the development of drugs to alter expression must move forward with great caution since overexpression of UCP-2, for example, reduces insulin secretion, thereby potentially worsening the hyperglycemia characteristic of diabetes [49,50]. Thus, while there is some conflicting evidence on the utility of increased UCP expression toward the protection from, or development of, the complications of diabetes, there is clear evidence that the coupling of the ETC to ATP production becomes dysregulated in diabetes which may lead to increased ROS and altered energetics (as reviewed in [173]).

Superoxide production may be a unifying mechanism that initiates, or least propagates, many of the mechanisms of neuropathy in diabetes. The aforementioned pathogenic elements from metabolic derangements (sorbitol, AGEs, PKC signaling) decreased upon inhibition of superoxide [183]. Mitochondrial function and DNA health was also improved upon inhibition of superoxide production in the retina in a model of diabetes [242]. The ROS control of these mechanisms is effected by DNA damage activated poly(ADP-ribose) polymerase (PARP). PARP catalyzes the inhibitory ADP-ribosylation of proteins, including GAPDH [80] (as reviewed in [177]), inhibition of which increases activity of the hexosamine pathway, PKC signaling activation, and AGE concentration [80]. Additionally, recent evidence has implicated PARP as not just a downstream signal of oxidative damage, but, instead, as a promulgator of ROS damage in a variety of tissues, including Schwann cells and the peripheral nerve [185]. PARP is directly neurotoxic due to the depletion of its cofactor, NAD⁺, when it is catalytically active [113]. Severe reduction of NAD⁺ results in energetic collapse of the cell and necrotic death [113].

In addition to ADP-ribosylation, superoxide may directly oxidize proteins to form carbonyl adducts that may modify protein function (as reviewed in [177]). Indeed, these modified proteins have been identified in the brain [70,202], although their function is not well studied. In addition to oxygen modification, ROS may lead to PARP mediated up regulation of iNOS followed by reaction of nitric oxide with superoxide to produce the reactive nitrogen radical [185]. Regardless of its source, nitric oxide may also modify proteins [185] to act in both damaging and protective capacities [168]. Nitric oxide and its radical may be a particularly important pathogenic mechanisms in the nervous system due to its use as both a neurotransmitter by neurons and regulator of blood flow secondary to nitric oxide mediated vasodilation [168]. The balance

between nitric oxide and its radical likely explains the observed protective and damaging effects of nitric oxide, since nitric oxide with its vasodilatory activity is likely protective, but its radical, that accumulates with increased ROS, likely mediates protein, and, thus, cellular, injury (as reviewed in [258]). Thus, the development of ROS and reactive nitrogen species (RNS) are a critical component of diabetes-induced damage that extends beyond simple radical chemistry to prolonged alterations of cellular signaling pathways.

CIPN, like diabetes, is also mediated by ROS (as reviewed in [65]). Both oxaliplatin and cisplatin have been shown to generate ROS [126], and mitochondria are damaged by ROS/RNS secondary to drug treatment [125]. Regardless of the source, these ROS damage additional cellular components such as proteins and lipids [65,77], ultimately leading to energetic failure [125] and apoptosis [126,218]. The result of these derangements include increased nociception as well as distal degeneration of intraepidermal nerve fibers, as is seen in animal models of CIPN caused by paclitaxel [23]. These data suggest that studies of CIPN must consider the distal most aspect of axons, and not just proximal segments seen in the sciatic nerve or dorsal roots since damage is not uniform.

ROS and RNS are also a prominent component of HIV, and its treatment-induced injury. The generation of these species appears to be most harmful to the neuronal cell body [115]. Antioxidant treatment improves cell survival but not neurite outgrowth [115], emphasizing the importance of ROS to somal, but not axonal, injury. Lehman and colleagues confirmed these observations in animal models of HIV infection, whereby the virus increased hydrogen peroxide production as well as oxidative and nitrosative protein modification in the sural, but not the sciatic, nerve [144]. The selectivity of sural nerve versus sciatic nerve may be due to the increased sensitivity of distal sensory fibers to mitochondrial dysfunction, as discussed previously [144].

2.4. Intracellular and inflammatory signaling

In diabetes, in addition to non-enzymatic modification of biomolecules, AGEs are also bioactive as ligands for two major types of cell surface receptors. The first discovered receptor, receptor for AGE (RAGE), was identified through the selective binding of glycosylated albumin to the surface of mouse macrophages with subsequently AGE/RAGE internalization [260,262], leading to macrophage proliferation in a granulocyte/macrophage colony stimulating factor (GM-CSF) dependent manner [292]. Since its identification, RAGE has been found to be expressed by a variety of cell types, including neurons (as reviewed in [230]). Vlassara et al., hypothesized that RAGE acts to clear harmful AGE modified proteins from the body [260]. Interestingly, the RAGE receptor also has a soluble isoform that is believed to be a scavenger receptor for AGEs and found in many tissues, including the adult nervous system [53]. A reduced level of this scavenger isoform is correlated with increased risk of peripheral neuropathy in patients with type II diabetes [13]. RAGE, however, is not simply a net to clear AGEs, but also can initiate an inflammatory response through cytokine release [289], including NF- κ B mediated transcriptional activation of pro-inflammatory cytokines TNF- α , IL-1 β , and MCP-1 [289], a pattern of cytokine expression that may facilitate tissue remodeling, as occurs in atherosclerosis [263]. RAGE has been identified on endothelial cells [178,217], and neurons [32], in vivo, which suggests an immune response with the concomitant increase in ROS could be initiated by AGEs in these tissues, thereby effecting additional vascular or neuronal injury [273]. In addition to tissue remodeling, the downstream effect of the induction of these cytokines may be the production of ROS, as monocytes from patients with diabetes have greater ROS production than control cells [79]. Cultured endothelial cells and AGE infused mice also demonstrate a RAGE dependent

increase in oxidative stress and NF- κ B induction upon exposure to AGEs [285]. Indeed, the antioxidant α -lipoic acid protects Schwann cells from AGE induced apoptosis in vitro [219]. Thus, RAGE converts the transient inflammatory signal of the AGE into a sustained inflammatory response that may lead to a long term inflammatory state, thereby hindering treatment [25,79].

After the identification of RAGE, three other receptors were identified (AGE-R1, AGE-R2, and AGE-R3) as part of a large AGE-receptor complex [288,264], (as reviewed in [259]). As a complex, AGE-R1/R2/R3 has been shown to be up regulated in the presence of AGEs with AGE-R3 demonstrating the greatest induction after exposure, and AGE-R2 phosphorylation increased in vitro upon exposure of human umbilical vein endothelial cells to AGE-BSA [232]. Together, these data suggest that AGE-R1 may serve as a stable receptor, while AGE-R2 effects the intracellular response through AGE-R3 following AGE-R2 tyrosine phosphorylation. The role of intracellular signaling by the AGE-R complex and the relevance of the previously identified activities of each component in the larger complex remain to be elucidated. Interestingly, early data on the AGE-R complex suggests AGE binding leads to a IL-1 dependent late induction of progrowth cytokine insulin-like growth factor (IGF-1) in monocytes in vitro [137], linking RAGE cytokine release to AGE-R response.

It should be noted that much of the work on the AGE-Rs has been performed in endothelial cells, reinforcing the importance of vascular injury, with concomitant ischemia, in the development of neuropathy, as is seen with RAGE. Current models suggest a delicate balance between the pro-inflammatory and tissue remodeling effects of RAGE and AGE clearance by the AGE-R complex [150], whereby AGE binding facilitates tissue remodeling and inflammatory cell recruitment, leading to vascular occlusion and neuronal/axonal injury. This model remains to be tested in vivo, however.

While the function of PARP in the regulation of metabolism through GAPDH modification and as an effector of ROS injury was previously discussed, it is also responsible for the regulation of inflammatory signaling. PARP was elegantly demonstrated to, upon exposure to inflammatory particles like LPS and TNF- α , increase transcription factors that lead to an increased expression of inflammatory cytokines and iNOS [112]. The expression of iNOS is particularly interesting, as its up regulation varied by cell type and stimulus [112]. Nitric oxide can also initiate damage through its radical as well as signal through in an independent cascade.

Nitric oxide serves as both a vasodilator and neurotransmitter that has a complex activity in neuronal signaling, damage, and repair with mixed data describing its protection from or contribution toward cellular damage and neuropathy (as reviewed in [306]). As described above, iNOS is induced in glia by PARP [113] where it serves an inflammatory function. However, in cultured endothelial cells, endothelial nitric oxide synthase (eNOS) has been shown to be down regulated in the setting of hyperglycemia, as a result of O-linked N-acetylglucosamine modifications secondary to activation of the hexosamine pathway, thereby increasing the risk of atherosclerosis and/or microvascular ischemia [82]. Interestingly, an early study conflicted with the previous data and found NOS and TNF- α to be induced in endothelial cells upon exposure to glycated albumin [7]. The authors of this study postulated that the NOS and AGE balance is critical for early and late development of diabetic complications, where nitric oxide is increased early in the disease through the activity of NOS, thereby damaging glomeruli through hyperfiltration, whereas AGE products serve to quench NO in the vasculature later in disease, thereby reducing vasodilatory capacity [7]. Thus, in the setting of hyperglycemia, reactive nitrogen intermediates may be produced within the nervous system as a result of PARP activation secondary to ROS damage while, concurrently, oxygen flow may be reduced through impaired mechanisms

of vasodilation. Together, the increase in iNOS and decrease in eNOS are two hits toward a toxic knockout of neurons and glia.

In addition to PARP and NOS signaling, neurotrophic factor signaling is also altered in diabetes. While all of the research discussed thus far has focused on the effect of hyperglycemia on nerve pathology, recent work has suggested that insulin, or the lack thereof, may also facilitate the development of the complications associated with type I diabetes. Indeed, Sima et al., suggest different nerve conduction properties between type I and type II diabetes may be a result of the loss of insulin and C peptide that classically occurs in type I diabetes [227]. C-peptide is derived from the same prohormone as insulin and is increasingly recognized as having distinct, albeit complementary, effects to the action of insulin (as reviewed in [265]). C-peptide will be lost at the same time as insulin, since they are both part of the same precursor peptide. The importance of the loss of C-peptide and insulin toward the development of the complications of diabetes was supported by more recent experiments showing diabetic animals had a reduced ability to up regulate neurotrophic factors (IGF-1, IGF-1 receptor, p75, and Trk A) in response to nerve crush injury, ultimately leading to reduced regenerative ability and decreased nerve fiber density [190,196]. This deficiency was largely selective for type I, not type II, diabetic models, suggesting that the deficiency of insulin and C-peptide, not hyperglycemia, leads to axonopathy and decreased nerve fiber density [196]. Evidence for the importance of insulin and C-peptide to the development of axonal defects in type I diabetes comes from rescue experiments where exogenous C-peptide improved conduction deficits, myelination defects, regenerative capacity, and nerve fiber number [226].

Additional work has clarified the protective role of the insulin induced neurotrophic factor insulin-like growth factor 1 (IGF-1). Given a decrease in insulin, as is seen in type I diabetes, it is perhaps unsurprising that IGF expression is decreased in patients with type I diabetes versus normoglycemic controls [190]. Long appreciated for its anti-apoptotic activity in cancer and injury (as reviewed in [256]), IGF-1 was recently found to protect DRG neurons from hyperglycemia induced apoptotic signaling [145].

Other signaling axes have been identified to be dysregulated in diabetes. Nerve growth factor (NGF) is well known to support sensory fiber survival in vitro and in vivo [58–60,146,147] and was recently demonstrated to be transiently up regulated in the DRGs of an animal model of type II diabetes during the onset of mechanical allodynia, suggesting dysregulated NGF signaling may facilitate the development of one of the hallmarks of diabetic neuropathy – pain [54]. NGF levels may be elevated at the onset of injury [54], facilitating the development of neuropathic pain, but then fall later in the course of the disease [93], thereby reducing regenerative capacity, although this pattern of expression may be dependent on the type of diabetes.

Altered signaling to increase inflammation is a prominent component of CIPN. In animals models of paclitaxel toxicity, ATF3, a general, transient marker of neuronal injury [250], is up regulated in DRG neurons within a day of drug administration, while glia increase expression of injury markers nearly a week after the first dose of the drug [195]. Additionally, markers of macrophage (CD68) and microglia (CD11b) activation increase one week following treatment [195]. These data show an evolving pathology whereby the DRG neurons are first harmed, then supporting glia in the DRG and nerve, which ultimately leads to recruitment or activation of inflammatory cells (macrophages, microglia) concomitant with symptom onset [194,195,272], and increased expression of many pro-inflammatory cytokines (as reviewed in [271]). Macrophage activation leads to matrix metalloproteinases-3 and -9 and, as a result, increased tissue degradation [182,225]. Thus, the chemotherapeutic agents increase inflammation in the

nerve and ganglia, which may then lead to tissue damage and more severe deficits.

Inflammatory signaling is a critical mechanism of HIV neuropathy. Indeed, both HIV proteins and systemic inflammation secondary to the viral infection may damage neurons and axons (as reviewed in [133,251]). Recent work has shown gp120 induces separate processes of injury in the neuronal soma versus the axon. In a compartmentalized culture of DRG neurons, gp120 reduces axonal length in an axon/Schwann cell only compartment and triggers apoptotic cell death when applied to the soma [165]. Interestingly, in the absence of Schwann cells, DRG soma were protected from apoptosis, but axons were still sensitive to the application of gp120 [165], suggesting different injury pathways were active in the two areas. Ultimately, Melli et al. found that this response is due to selective binding of gp120 to chemokine receptors on axons which leads to caspase activation, and, thus, injury and degeneration [165]. The engagement of apoptotic machinery in the soma, however, was distinct from the mechanisms in the axons as suggested by the Schwann cell dependence of soma apoptosis in response to gp120 [165]. Additional work found gp120 binding to chemokine receptor CXCR4 on Schwann cells in the DRG to result in the release of the ligand RANTES (regulated upon activation, normal T-cell expressed and secreted). RANTES then binds to a different chemokine receptor (CCR5) on the neuron, leading to release of TNF- α by neurons and autocrine apoptotic signaling through its receptor and the c-Jun cascade [26,134]. The importance of CXCR4 and CCR5 to the development of HIV neuropathy also extends to the initiation of inflammation [127]. VPR has been shown to evoke very similar, pro-inflammatory responses in DRG neurons [2]. In addition to the activation of cell mediated inflammation, Apostolski, et al. showed gp120 may mediate DRG neuron cell death by activation of the complement cascade [11]. Thus, HIV may enter the peripheral nervous system through other cells, but its proteins and the immune response may indirectly damage neuron cell bodies and axons, albeit through slightly different mechanisms.

In addition to the inflammation from the virus, recent work has identified antiretrovirals to also increase inflammatory signaling [303] and activation of apoptotic machinery [26]. To this end, ddC increases expression of TNF- α in GFAP⁺ cells in the dorsal horn and neurons in the DRG [303]. In addition to TNF- α , BDNF has also been shown to facilitate the development of mechanical and thermal hyperalgesia following treatment by a nucleoside analog by increasing firing rates of dorsal horn neurons to stimuli [204]. This finding suggests ddC increases BDNF release which ultimately leads to enhanced synaptic connectivity between primary nociceptors and dorsal horn neurons. Thus, in addition to the inflammatory signaling from the virus itself, the antiretrovirals may also initiate damage through modulation of the inflammatory response via TNF- α and synaptic connectivity via BDNF.

Aberrant inflammatory signaling is the primary pathogenic mechanism of HCV neuropathy. As discussed previously, while cryoglobulinemia is not necessary for the development of peripheral neuropathy, it changes the symptom constellation from a localized neuropathy to a more generalized disorder affecting multiple nerves. Cryoglobulinemia has long been appreciated to precipitate peripheral neuropathy [48]. Sural nerve histology of a patient with cryoglobulinemia showed small and medium vessel perivascular inflammation with some vessels completely occluded and myelin degeneration [48]. IgM and IgG were found deposited on smaller vessels, while fibrinogen was readily stained on the larger vessels [48]. The authors of this report suggest the patient's neuropathy was precipitated by the cryoglobulinemia, whereby IgGs bound to myelin, leading to direct immune attack, as well as to the small and medium vessels, leading to vascular occlusion and ischemia. A different study found that the antibodies binding to myelin were largely against myelin associated glycoprotein

(MAG) [244]. Thus, the IgG and IgM antibodies may cause damage through two mechanisms: activation of complement on myelin and ischemia by precipitation of immune complexes and lymphocytic inflammation within the vasa nervorum, causing luminal narrowing or occlusion [29,244]. While these mechanisms may explain the neuropathy in patients with HCV and cryoglobulinemia, recall that 30–70% of patients with HCV neuropathy may not have cryoglobulins. In these patients a different mechanism must be responsible for their symptoms.

Interferon- α (IFN- α) modulates the development of peripheral neuropathy in patients infected with HCV. Both IFN- γ and IFN- α are cytokines that are released during viral infection to induce an “antiviral”, intracellular state. IFN- α can be induced by most cells, while IFN- γ is specifically released by lymphocytes as part of the cell mediated immune response (as reviewed in [92]). In addition to endogenous induction of IFN- α by HCV, given its general antiviral activity, exogenous IFN- α has become a critical component of combination therapy for certain HCV infections (as extensively reviewed in [222]). Interestingly, autoimmunity increases following IFN- α monotreatment in HCV infection [88], despite a decrease in cryoglobulins and viral titer. This suggests that IFN- α produces a pro-inflammatory state that may facilitate damage to the vasa nervorum and myelin. Thus, it is a fine balance between inflammation to clear the virus and autoimmunity. This autoimmunity likely initiates the development of neuropathy in HCV; there is a combination of ischemia due to occluded small vessels and direct attack against the myelin. This model is consistent with the non-dependence of neuropathy on the presence of cryoglobulins. While the cryoglobulins may increase vascular inflammation, leading to ischemia and more widespread neuropathy, anti-myelin proteins may still be present in the absence of cryoglobulins, so neuropathy may still develop. It is still unclear how ribavirin may reduce the incidence of neuropathy, but one possibility is by leading to more complete viral clearance, ribavirin reduces systemic inflammation, including cryoglobulins and anti-MAG antibodies. By reducing these compounds, IFN- α autoimmunity, and, thus, neuropathy, is less likely to develop. This hypothesis remains to be tested.

2.5. Axonal transport defects

Diabetes also affects axonal health by modulation of axonal transport. Nearly 30 years ago, Medori et al. identified impaired slow axonal transport of cytoskeletal proteins neurofilament (light and medium subunits), tubulin, and actin in an animal model of type I diabetes versus healthy controls [164]. The authors also observed increased axonal cross sectional area in the proximal aspect of the axon, but a reduced area in the distal aspect. They hypothesized that this pattern may be a result of reduced accumulation of cytoskeletal elements distally because of impaired transport [164]. Additional cytoskeletal protein defects include direct actin and neurofilament glycation in the setting of hyperglycemia in vitro [34], and in vivo [69,191] (as reviewed in [163]), as well as reduced expression of heavy and light neurofilament, and α -tubulin in the DRGs of type I diabetic animals [172]. It should be noted, however, that while actin glycation does not interfere with its ability to polymerize [191], glycosylated tubulin has a reduced polymerization ability [274]. The expression and modification of these cytoskeletal proteins (actin, neurofilament, tubulin) is believed to interfere with cytoskeletal assembly, and, thus, axonal transport [163]. RAGE is predicted to interact with actin through its effector mDia1 [124,129,157], but recent work has elegantly shown that slowed axonal transport in diabetic animals is independent of RAGE expression [129]. Despite the slowed transport of the RAGE/actin effector protein mDia1 in diabetic animals (wild type and RAGE knockout), RAGE itself was not differentially present

between diabetic and control animals. While the exact mechanisms of slowed axonal transport in diabetes, and how it may effect other cellular processes, remains to be elucidated, one can imagine that such large scale changes in the cell may alter its ability to respond to its environment, perhaps making it more susceptible to damage through other mechanisms or less efficient with cellular repair and regeneration.

Microtubule defects with the concomitant transport difficulties is a critical component of paclitaxel-induced CIPN with much work focusing on how microtubule stabilization by taxanes, in particular, may interfere with axonal transport (as reviewed in [106]). Incubation of DRG neurons with high levels of paclitaxel has been shown to interfere with anterograde transport of HRP [243]. Interestingly, while paclitaxel binds to the lumen of microtubules and, thus, cannot directly hinder motor movement [106], electron microscopy shows decreased rates of microtubule crosslinks and reduced density of the cross-linking microtubule associated proteins upon DRG neuron exposure to paclitaxel in vitro [243]. The dearth of these crosslinks could alter transport dynamics. Alternatively, increased microtubule density and aggregation [46,106,243] may hinder motor movement. However, these microtubule abnormalities have not been observed in patient sural nerve biopsies [211], perhaps due to lower drug concentrations.

An alternative hypothesis of transport interference in paclitaxel mediated CIPN is covalent modification of tubulin interfering with molecular motor function. As a microtubule polymerizes, the tubulin components that are not on the elongating end can be acetylated, glutamated, and detyrosinated to increase stability (as reviewed in [106]). Investigations of dendrite/axon identity have found tubulin detyrosination to organize distribution and movement of kinesin along the axon [83,139]. Paclitaxel enhances all three posttranslational modifications, thereby disrupting axon/soma/dendrite polarity [117,276]. The role of posttranslational modification is complex, however, as each modification can alter motor binding and motility [106], and different motor subtypes may bind to different modified tubulins preferentially [41]. Nonetheless, interruption of transport may lead to poor anterograde transport of vesicles and organelles, as well as retrograde transport of trophic factors [106]. Transport dynamics may also be affected at the end of the axon, where motors must release from and reattach to different microtubules. Indeed, a recent paper has shown that in a drosophila model of a degenerative motor neuron disease with a tubulin binding domain mutation in a subunit of dynein, dynein accumulates in the terminal bouton because of a failure to bind to the end of the microtubule [149]. The microtubule end and motor dynamics are critical for maintaining proper and equitable delivery of vesicles to terminal boutons [277]. This model suggests dysfunction of transport could lead to derangements at the axon terminal and, thus, interfere with communication or organelle delivery and lead to terminal degeneration, although this hypothesis has not been tested.

Surprisingly, low dose paclitaxel has been shown to facilitate regeneration, rather than degeneration, in the central nervous system [120]. The authors of this initial study suggested paclitaxel may facilitate regeneration by reducing scarring [120]. An additional hypothesis was proposed three years prior to the discovery of the regenerative benefit of low dose paclitaxel. Witte et al. suggested that since paclitaxel modifies neuron polarity to create multiple axons from one cell, perhaps low dose paclitaxel may be helpful to “convert a nongrowing minor neurite into a growing axon” to facilitate central nervous system regeneration [276]. Thus, the microtubule stabilizing dynamics must be delicately balanced between stable and unstable, polymer and monomer, such that paclitaxel may either cause axonal degeneration through interruption of axonal transport or regeneration by stabilization of growing neurites.

Axonal transport defects are also observed in CIPN caused by cisplatin and bortezomib. As with paclitaxel, in a model of bortezomib CIPN, tubulin polymerization is increased in vivo and in vitro upon clinically appropriate drug concentration [167]. The exact mechanism of bortezomib tubulin stabilization remains to be elucidated. In addition to bortezomib and paclitaxel, early studies on cisplatin neurotoxicity showed impaired anterograde and retrograde fast transport in vitro with no gross morphologic abnormalities [210]. The authors of this study suggested cisplatin may be directly toxic to kinesin and dynein through crosslinking or motor ATPase inhibition [210], although little work has been pursued in this line of research.

2.6. Channelopathy

While diabetes does have some sodium/potassium channel dysfunction [107], as discussed with respect to metabolic deregulation and conduction velocity, the details of direct channel modulation in diabetes is still unclear [254]. However, channel defects are some of the fundamental dysfunctions in CIPN and GBS.

In CIPN, channel toxicity is especially relevant for platinum compounds and proteasome inhibitors. Of the platinum chemotherapeutics, oxaliplatin has the largest effect on channels. Indeed, recall that oxaliplatin has two types of neuropathy: an acute as well as a more chronic form [22]. Thus far, the chronic neuropathy with numbness and functional impairment has been discussed. However, the acute neuropathy is characterized by transient cold hypersensitivity and paresthesias, which generally resolve on their own and do not require dose changes [22]. Acute abnormalities of nerve, hippocampal neurons, and DRG neurons are observed in vitro after just 45 min of oxaliplatin exposure, where sodium current is drastically increased to produce larger compound action potentials in response to depolarization [4]. These abnormalities were abrogated with a sodium channel blocker, suggesting modification of these channels likely contribute to the abnormality [4], and the increased refractory period of the neuron suggested that it was the modification of the voltage gated ion channel inactivation, in particular, that was altered by exposure to oxaliplatin [4], with no effect on potassium channels [33]. The mechanisms of specific sodium channel sensitization remain to be elucidated, however, and a general increase in sodium current does not explain the specific cold hypersensitivity observed in oxaliplatin CIPN.

Cold hypersensitivity is instead most likely due to oxaliplatin triggered sensitivity in TRP channels, including the capsaicin receptor (TRPV1) and “cold” receptors (TRPA1 or TRPM8) [8]. While oxaliplatin fails to directly modulate these receptors, cAMP rapidly increases in concentration upon drug exposure, suggesting cAMP is a second messenger to a signaling cascade initiated by oxaliplatin that leads to TRP channel modification [8]. Additionally, Descoeur et al. identified two potassium channels, TREK1 and TRAAK, to be drastically reduced in expression, while the expression of two depolarizing channels, the sodium channel and hyperpolarization activated channel (HCN), were slightly elevated [75]. These changes appeared to specific for cold sensing neurons [75]. Thus, oxaliplatin treatment causes a global change in ion channel expression that leads to a higher membrane potential and, thus, more robust firing of TRP channels. Additionally, modeling experiments by Dimitrov et al. have suggested [78] that the reduction in potassium current in internodal regions of myelinated axons could lead to the nerve fiber defects first observed by Adelsberger et al. [4], with action potential trains, and thus a stronger central response following a small peripheral stimulus.

In addition to cisplatin, bortezomib has also been shown to interfere with ion channels. In a recent animal study with both acute (single dose) and chronic (multiple dose) administration of bortezomib, the authors found mechanical hyperalgesia and

an increase in protein levels of TRPV1 in DRGs and spinal cord [201]. Interestingly, the transcript levels of TRPV1 and CGRP were reduced in these tissues, suggesting the protein levels likely increase because of bortezomib's inhibition of the proteasome [201], thereby potentially increasing neuronal response to nociceptive stimuli. Additionally, patients treated with bortezomib had increased resting membrane potential, which would lead to increased neuronal response for a given input. This change in potential preceded axonal degeneration [176]. Degeneration was suggested by the authors to be due to energetic collapse in the axon, from mitochondrial dysfunction leading to impaired Na^+/K^+ ATPase activity and, thus, intraaxonal accumulation of sodium ions [176] and increased calcium influx by reversal of the sodium/calcium exchanger [233]. This influx of calcium may begin the path to apoptosis. This hypothesis remains to be tested, however. Nonetheless, channel dysfunction and changes in membrane polarization appear to be a critical mechanism for the development of hyperexcitability and acute symptoms of CIPN, especially from platinum chemotherapeutics and proteasome inhibitors.

While little work has examined the electrophysiological effect of HIV or its proteins on DRGs, there do appear to be some subtle changes. Chiefly, both gp120 [188] and Vpr [2] have been shown to increased DRG neuron excitability, perhaps through the influx of calcium following activation of the chemokine receptors. In macrophages, gp120 binding to chemokine receptors has been shown to directly regulate calcium, potassium, and chloride transport [148].

While channel dysfunction has not been identified as a pathogenic mechanism in HCV neuropathy, the node of Ranvier is the primary insult in GBS. Much work by Yuki and others have shown molecular mimicry between *C. jejuni* antigens and gangliosides results in immune attack of the node of Ranvier. The first clues to the pathophysiology were the association of anti-GM1 ganglioside antibodies with the AMAN form of GBS following *C. jejuni* infection [121,296]. The presence of these antibodies predicted a reversible conduction block, believed to be due to disruption of the node of Ranvier [138,141]. The deposition of these antibodies leads to complement deposition on the axolemma [114] and, thus, disruption of axons/Schwann cell architecture at the node and paranodal regions [43], ultimately leading to disruption of ion channel organization at the node of Ranvier [235]. More specifically, antibody deposition and complement activation increases potassium current in the paranodal region and decreases sodium current in the node, thereby leading to conduction failure [239]. While this may be the mechanism of block, it does not link *C. jejuni* to the development of autoantibodies.

A key breakthrough in the understanding of the pathophysiological link between *C. jejuni* and GBS came from Yuki and colleagues when they found rabbits that were inoculated with GM1 ganglioside developed the axonal phenotype of GBS [295]. In a follow up study using this in vivo model, Yuki, et al. found the lipooligosaccharide of *C. jejuni* to be sufficient to induce anti-GM1 antibodies and paralysis consistent with GBS, and that the anti-GM1 antibodies were sufficient to induce the symptoms [294]. The findings suggest GBS is the result of molecular mimicry between *C. jejuni* antigens and host gangliosides [294]. Much like Koch's postulates for infectious organisms, Ang, Jacobs, and Laman proposed a number of criteria to define molecular mimicry between pathogen antigens and host tissue as a cause of autoimmune disease [10]. These include 1. Epidemiological association between pathogen and disease, 2. Identification of antibodies against self antigens, 3. Identification of the pathogen's antigen that elicits the self antibodies, and 4. Recapitulation of the disease in an animal model [10]. *C. jejuni* and GBS successfully filled all criteria and is thus considered to be a genuine example of molecular mimicry between a pathogen and host molecular that leads to an autoim-

mune disease [10]. After the identification of the *C. jejuni*/GM1 relationship, other pathogen/antigen links were identified for GBS, including anti-GD1a ganglioside [122], anti-neurofascin [76,200] as well as antibodies against other nodal/paranodal proteins including gliomedin and contactin [76]. The motor selectivity of the AMAN subtype of GBS may be due to differential ganglioside expression between motor and sensory axons and myelin [186], with GM1 found mainly in motor myelin [187]. However, these results were challenged in a later, larger study [237], suggesting more work is needed to separate the ganglioside composition of both motor and sensory axons and myelin in both healthy controls and patients who develop GBS. Nonetheless, anti-ganglioside antibodies that interfere with the node of Ranvier appear to be common in many of the sensory and motor subtypes of GBS, with specific ganglioside targets being more prevalent in certain subtypes [236].

Thus, a variety of diseases and neuropathies are caused by only a few mechanisms: mitochondrial dysfunction and ROS, altered signaling and inflammation, and finally reduced axonal transport and channel dysfunction. While these pathophysiological mechanisms inevitably will be valuable for therapeutic design, recent advances into the downstream effectors of degeneration reveal fundamental mechanisms of axonal degeneration and promise to be essential for the development of treatments that may be applied universally to degeneration caused by disease as well as trauma.

3. New insights into mechanisms of degeneration

Wallerian degeneration is the process whereby an injured axon degrades and debris is cleared to facilitate axonal regeneration and recovery. Axonal degeneration is not a passive process like a wire being broken, however. Rather, it is an active process that requires axon to soma signaling. This type of self-destructive pathway is reminiscent of apoptosis, but the pathways of axonal degeneration have been shown to be independent of caspases and apoptotic signaling [97]. One can imagine this signaling may be through an active “injury” signal or the loss of a “survival” signal. Early studies suggested axonal degeneration is a result of the former case. After axotomy, there is a delayed influx of calcium with subsequent activation of the calcium activated protease calpain and other proteases that is necessary and sufficient for axon degeneration and digestion of the cytoskeleton [103,153,286]. Interestingly, inhibition of calpain does delay Wallerian degeneration, but chelation has a much more robust effect, suggesting the influx of calcium likely has multiple roles, in addition to the activation of calpain [297]. This calcium influx marks a late step toward axonal degeneration (once proteins begin to be degraded, the process cannot be reversed), suggesting it is the result of up stream signaling, but what is this signal, and what are the components of this pathway?

A curious inbred mouse strain was reported to have delayed Wallerian degeneration where the axons in a transected nerve remained largely intact three days after injury, a time point where robust degeneration normally has begun [151]. Later studies identified the mutant gene responsible for this slowed Wallerian degeneration, *Wld^S*, [152,193] as a fusion of ubiquitination factor E4B (Ube4b) and nicotinamide mononucleotide adenylyl-transferase (Nmnat). The fusion protein is chiefly found in the nucleus of these animals [154], although its protective activity depends on its activity in the axon [57,214]. The Ube4b:Nmnat fusion results in increased stability of Nmnat versus wild type Nmnat [105]. Studies in mice and drosophila have shown that the axon protective effects of the *Wld^S* gene product requires the activity of Nmnat [16,215], while the Ube4b fusion allows the *Wld^S* gene product to bind to another protein, which may localize the protein fusion to the axon or mitochondria and/or allow it to interact with additional, unknown proteins [16]. While Nmnat appears

to be critical for axonal protection [16,216,298], the classic product of Nmnat reactions, NAD, is not required intracellularly for resistance to degeneration [216], despite protection from degeneration with exogenous, extracellular NAD application in vitro [267]. These data suggest that both extracellular NAD and preserved Nmnat function protect axons from degeneration but through two distinct mechanisms [216,298]. The secondary activity of Nmnat may be chaperone activity [299] or regulation of mitochondrial metabolism [283]. Nmnat has been shown to be active within the mitochondria. Several studies have shown Nmnat to reduce calcium spikes after axotomy [3,15], which ties the early stages of axonal degradation signaling to the later calcium dependent phase discussed above. Additionally, the *Wld^S* gene product has been shown to modulate energy metabolism within the axon to maintain ATP levels following injury [221] as well as to reduce ROS production [184,199].

This arrangement of the pathway suggests that, in contrast to the late injury signal of calcium, Nmnat may produce a survival signal that is lost during axonal injury. Indeed, when the MPTP is activated in *Wld^S* mice, axons degenerate, which confirms the upstream position of Nmnat to calcium signaling [21]. If Nmnat is transported throughout the axon [105], reduced transport may increase distal axon sensitivity to degeneration due to reduced Nmnat levels, tying this mechanism to the axonal transport defect pathways. Additionally, E3 ligases have been shown to balance degeneration and regeneration, where increased activity of an E3 ligase reduces Nmnat expression, thereby initiating degeneration [18,281], while inhibition of the proteasome system resists Wallerian degeneration [297]. Thus, Nmnat likely acts as a survival signal that is actively distributed throughout the axon. Once an axon is injured, Nmnat levels decrease, ultimately leading to calcium influx and activation of calcium dependent proteases and degradation of the axon (as reviewed in [61]). *Wld^S* interferes with this process by resisting decreases in NMNAT concentration.

A loss of function mutation of a component of Toll-like receptor signaling has been found to phenocopy the gain of function of the *Wld^S* gene product, presenting an additional therapeutic target for protection from axon degeneration. A member of the Toll-like receptor (TLR) adaptor family, SARM/MyD88-5, was first identified to negatively regulate TLR signaling [44] and to be expressed in vivo in neuronal mitochondria and microtubules where it associates with JNK3 in vitro [136], a pathway known to be critical for axon degeneration [223]. SARM null mice are resistant to cell death following oxygen and glucose deprivation, suggesting SARM, like Nmnat, may be critical for neuron degeneration and death signaling [136]. These findings were extended to axon degeneration more specifically, where SARM loss of function resulted in resistance to axon degeneration following axon transection [189] and withdrawal of trophic support in vitro [104]. SARM may also be activated by CaM kinase, linking this pathway to the calcium influx characteristic of axonal degeneration [189]. It is likely that SARM is a common pathway toward axon degeneration from various insults, as is the case with the downstream JNK signaling, which may be activated by SARM or by an additional emerging pathway involving dual leucine kinase (DLK) [170]. Thus, the axon degeneration pathway appears to contain many points of convergence such that many different types of insults may result in initiation of a common degradation pathway.

These data suggest a model of the active process of axon degeneration. The balance of proteasomal degradation and active transport maintain Nmnat expression at a constant, steady state level. In the setting of an injury, either one of these processes may be affected such that Nmnat levels fall below a threshold. The decrease in Nmnat then triggers calcium influx and release from mitochondria, which activates calpain. Alternatively, calpain may be activated by SARM (which is itself stimulated by injury) with JNK




Fig. 2. Summary of the mechanisms of peripheral nerve degeneration. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Peripheral neuropathy in a wide range of disease, including diabetes, CIPN, viral infections, and GBS, develops as a result of the interaction of various combinations of just six processes: altered metabolism, covalent modification, impaired organelle function with ROS/RNS, altered signaling, slowed axonal transport, and altered ion channel dynamics. The figure delineates which process is active in which disease by color, as shown in the key. All of these processes interact to ultimately converge on the neuronal death and/or axonal degeneration pathways, with the major interactions outlined in the above figure. The different black, dark gray, and light gray coloring of the arrows is for clarity only.

signaling. Calpain then leads to protein degradation. Additionally, DLK may activate JNK in parallel to Nmnat loss or act to signal a different type of insult. Clearly, the details of the axonal degeneration process continue to be elucidated and much work must be done to clarify how *Wld^S* (Nmnat), SARM, and DLK converge or diverge. Any insult that activates this pathway or modulates any of the components, as in mitochondrial dysfunction or slowed axonal transport, will lead to axonal degeneration, as is seen in diabetes, CIPN, HIV neuropathy, HCV neuropathy, and GBS (Fig. 2). Interestingly, Nmnat has been shown to be regulated by PKC and to modulate PARP, which links Nmnat activity to two additional points of injury in neuropathy, as discussed above [24].

4. Conclusion

While a variety of insults, including diabetes, chemotherapy, HIV, HCV, and *C. jejuni* may lead to peripheral neuropathy, there are only a handful of mechanisms that cause it. These include altered metabolism, covalent modification of proteins, reduced organelle efficiency with concomitant increases in ROS and RNS production, altered intracellular signaling (e.g. PKC, RAGE) and increased inflammation, reduced axonal transport, and modulation of ion channel expression and/or dynamics (Fig. 2). Alterations in metabolism, as seen in diabetes, may modulate the flux through different metabolic pathways with concomitant changes in reactive metabolites. Many of these mechanisms are intrinsically linked, such as slowed mitochondrial transport exacerbating the accumulation of mitochondrial mutations during the normal aging process, or the increase in ROS associated with mitochondrial dysfunction.

Downstream of the damage from the pathophysiological processes, in a paradigm reminiscent of apoptosis, degeneration occurs in an early, non-committed (“survival”) and late (“death”) stage of

degeneration marked by the increase in calcium and protease activation. While the details of this processes are still being elucidated, current data suggest that within the axon, Nmnat acts as a survival signal that decreases during axonal injury. This fall leads to the initiation of the degeneration pathway. While the mechanism whereby Nmnat modulates downstream effectors such as calcium is still being investigated, its potential role in mitochondrial metabolism is particularly interesting, given the importance of this organelle to the generation of neuropathy through many diseases. The multipurpose role of Nmnat in NAD metabolism, chaperone activity, and mitochondrial function regulation suggests that it may protect different pathologies in a variety of ways, with one modality not being protective for all diseases (as proposed in [64] and observed in transection versus Charcot-Marie-Tooth disease [169]). Clearly, the protective effect of the *Wld^S* transgene is multifaceted and only now starting to be understood.

The promise of the *Wld^S* and SARM models of resistance of axonal degeneration in the generation of pan-disease neuro-protectants is reflected in the many experiments showing the *Wld^S* gene to protect against neuropathy in a variety of diseases, including models of spinocerebellar ataxia [299], CIPN [268,269], diabetes [278,304], myelinopathy [212], progressive motor neuronopathy [94], Charcot-Marie-Tooth disease [169], traumatic axon injury [169,266], and spinal muscular atrophy [169]. However, the *Wld^S* gene does not cure all deficits of these diseases. Indeed, *Wld^S* does not protect against disease onset or synapse abnormalities in the model of spinal muscular atrophy [169], and it loses its effectiveness in protection from degeneration with advanced age [192]. While research continues to uncover the axonal degeneration pathway, the initiating apparatus of this pathway and how it interacts with other pathways (i.e., DLK) or components (e.g., SARM) have still not been uncovered.

Clearly, while there are many new exciting avenues of research into the unifying mechanisms of neuropathy, and how modulation of these mechanisms may help treat or prevent neuropathy, there is still much work that needs to be done in understanding how axons become more susceptible to injury and degeneration with age, as well as what, if any, commonality there is between the pathways of development, degeneration, and regeneration (Fig. 2).

Acknowledgements

This work was supported by the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, NINDS (R01 NS-43991), and the Foundation for Peripheral Neuropathy. The authors wish to thank Catherine Kiefe for her artistic talents and expertise in the production of figure two.

References

- [1] U.J.P.o.H.A. (UNAIDS), Global report: UNAIDS report on the global AIDS epidemic: 2010.
- [2] S. Acharjee, F. Noorbakhsh, P.L. Stemkowski, C. Olechowski, A. É. Cohen, K. Ballanyi, B. Kerr, C. Pardo, P.A. Smith, C. Power, HIV-1 viral protein R causes peripheral nervous system injury associated with in vivo neuropathic pain, *FASEB J.* 24 (2010).
- [3] R. Adalbert, G. Morreale, M. Paizs, L. Conforti, S.A. Walker, H.L. Roderick, M.D. Bootman, L. Siklós, M.P. Coleman, Intra-axonal calcium changes after axotomy in wild-type and slow Wallerian degeneration axons, *Neuroscience* 225 (2012) 44–54.
- [4] H. Adelsberger, S. Quasthoff, J. Grosskreutz, A. Lepier, F. Eckel, C. Lersch, The chemotherapeutic oxaliplatin alters voltage-gated Na⁺ channel kinetics on rat sensory neurons, *Eur. J. Pharmacol.* 406 (2000) 25–32.
- [5] B.M. Allos, *Campylobacter jejuni* infections: update on emerging issues and trends, *Clin. Infect. Dis.* 32 (2001) 1201–1206.
- [6] M. Amadori, Atti R. Accad. Lincei 2 (1925) 337–342.
- [7] A. Amore, P. Cirina, S. Mitola, L. Peruzzi, B. Gianoglio, I. Rabbone, C. Sacchetti, F. Cerutti, C. Grillo, R. Coppola, Nonenzymatically glycated albumin (Amadori adducts) enhances nitric oxide synthase activity and gene expression in endothelial cells, *Kidney Int.* 51 (1997) 27–35.
- [8] U. Anand, W.R. Otto, P. Anand, Sensitization of capsaicin and icilin responses in oxaliplatin treated adult DRG neurons, *Mol. Pain* 6 (2010) 1–11.
- [9] T.D. Anderson, A. Davidovich, R. Arceo, C. Brosnan, J. Arezzo, H. Schaumburg, Peripheral neuropathy induced by 2',3'-dideoxycytidine. A rabbit model of 2',3'-dideoxycytidine neurotoxicity, *Lab. Invest.* 66 (1992) 63–74.
- [10] C.W. Ang, B.C. Jacobs, J.D. Laman, The Guillain-Barré syndrome: a true case of molecular mimicry, *Trends Immunol.* 25 (2004) 61–66.
- [11] S. Apostolski, T. McAlarney, A.P. Hays, N. Latov, Complement dependent cytotoxicity of sensory ganglion neurons mediated by the gp120 glycoprotein of HIV-1, *Immunol. Invest.* 23 (1994) 47–52.
- [12] A.A. Argyriou, A. Kyritsis, T. Makatsoris, H. Kalofonos, Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature, *Cancer Manag. Res.* 6 (2014) 135–147.
- [13] C.E. Aubert, P.-L. Michel, P. Gillery, S. Jaisson, M. Fonfrede, F. Morel, A. Hartemann, O. Bourron, Association of peripheral neuropathy with circulating advanced glycation end products, soluble receptor for advanced glycation end products and other risk factors in patients with type 2 diabetes, *Diabetes Metab. Res. Rev.* 30 (2014) 674–685.
- [14] F.-J. Authier, G. Bassez, C. Payan, L. Guillevin, J.-M. Pawlotsky, J.-D. Degos, R.K. Gherardi, L. Belec, Detection of genomic viral RNA in nerve and muscle of patients with HCV neuropathy, *Neurology* 60 (2003) 808–812.
- [15] M.A. Avery, T.M. Rooney, J.D. Pandya, T.M. Wishart, T.H. Gillingwater, J.W. Geddes, P.G. Sullivan, M.R. Freeman, Wld⁵ prevents axon degeneration through increased mitochondrial flux and enhanced mitochondrial Ca²⁺ buffering, *Curr. Biol.* 22 (2012) 596–600.
- [16] M.A. Avery, A.E. Sheehan, K.S. Kerr, J. Wang, M.R. Freeman, Wld⁵ requires Nmnat1 enzymatic activity and N16-VCP interactions to suppress Wallerian degeneration, *J. Cell Biol.* 184 (2009) 501–513.
- [17] P.W. Baas, M.M. Black, Individual microtubules in the axon consist of domains that differ in both composition and stability, *J. Cell Biol.* 111 (1990) 495–509.
- [18] E. Babetto, B. Beirowski, E.V. Russler, J. Milbrandt, A. DiAntonio, The Phr1 ubiquitin ligase promotes injury-induced axon self-destruction, *Cell Rep.* 3 (2013) 1422–1429.
- [19] R.S. Balaban, S. Nemoto, T. Finkel, Mitochondria, oxidants, and aging, *Cell* 120 (2005) 483–495.
- [20] G. Barja, A. Herrero, Localization at complex I and mechanism of the higher free radical production of brain nonsynaptic mitochondria in the short-lived rat than in the longevous pigeon, *J. Bioenerg. Biomembr.* 30 (1998) 235–243.
- [21] S.A. Barrientos, N.W. Martinez, S. Yoo, J.S. Jara, S. Zamorano, C. Hetz, J.L. Twiss, J. Alvarez, F.A. Court, Axonal degeneration is mediated by the mitochondrial permeability transition pore, *J. Neurosci.* 31 (2011) 966–978.
- [22] B.K. Bennett, S.B. Park, C.S.-Y. Lin, M.L. Friedlander, M.C. Kiernan, D. Goldstein, Impact of oxaliplatin-induced neuropathy: a patient perspective, *Support Care Cancer* 20 (2012) 2959–2967.
- [23] G.J. Bennett, G.K. Liu, W.H. Xiao, H.W. Jin, C. Siau, Terminal arbor degeneration – a novel lesion produced by the antineoplastic agent paclitaxel, *Eur. J. Neurosci.* 33 (2011) 1667–1676.
- [24] F. Berger, C. Lau, M. Ziegler, Regulation of poly(ADP-ribose) polymerase 1 activity by the phosphorylation state of the nuclear NAD biosynthetic enzyme NMN adenylyl transferase 1, *Proc. Natl. Acad. Sci.* 104 (2007) 3765–3770.
- [25] A. Bierhaus, P.M. Humpert, M. Morcos, T. Wendt, T. Chavakis, B. Arnold, D.M. Stern, P.P. Nawroth, Understanding RAGE, the receptor for advanced glycation end products, *J. Mol. Med.* 83 (2005) 876–886.
- [26] A. Bodner, P.T. Toth, R.J. Miller, Activation of c-Jun N-terminal kinase mediates gp120IIIB- and nucleoside analogue-induced sensory neuron toxicity, *Exp. Neurol.* 188 (2004) 246–253.
- [27] W. Boehmerle, U. Spittgerber, M.B. Lazarus, K.M. McKenzie, D.G. Johnston, D.J. Austin, B.E. Ehrlich, Paclitaxel induces calcium oscillations via an inositol 1,4,5-triphosphate receptor and neuronal calcium sensor 1-dependent mechanism, *Proc. Natl. Acad. Sci.* 103 (2006) 18356–18361.
- [28] W. Boehmerle, K. Zhang, M. Sivula, F.M. Heidrich, Y. Lee, S.-E. Jordt, B.E. Ehrlich, Chronic exposure to paclitaxel diminishes phosphoinositide signaling by calpain-mediated neuronal calcium sensor-1 degradation, *Proc. Natl. Acad. Sci.* 104 (2007) 11103–11108.
- [29] B. Bonetti, F. Invernizzi, N. Rizzuto, M.L. Bonazzi, G. Zanusso, G. Chinaglia, S. Monaco, T-cell-mediated epineural vasculitis and humoral-mediated microangiopathy in cryoglobulinemic neuropathy, *J. Neuroimmunol.* 73 (1997) 145–154.
- [30] O. Boss, T. Hagen, B.B. Lowell, Uncoupling proteins 2 and 3: potential regulators of mitochondrial energy metabolism, *Diabetes* 49 (2000) 143–156.
- [31] O. Boss, S. Samec, A. Paoloni-Giacobino, C. Rossier, A. Dulloo, J. Seydoux, P. Muzzin, J.-P. Giacobino, Uncoupling protein-3: a new member of the mitochondrial carrier family with tissue specific expression, *FEBS Lett.* 408 (1997) 39–42.
- [32] J. Brett, A.M. Schmidt, S.D. Wan, Y.S. Zou, E. Weidman, D. Pinsky, R. Nowygrod, M. Nepper, C. Przysiecki, A. Shaw, A. Migheli, D. Stern, Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues, *Am. J. Pathol.* 143 (1993) 1699–1712.
- [33] A. Broomand, E. Jerremalm, J. Yachnin, H. Ehrsson, F. Elinder, Oxaliplatin neurotoxicity-no general ion channel surface-charge effect, *J. Negat. Results Biomed.* 8 (2009).
- [34] M.R. Brown, T.J. Keith, H.R. Knull, Nonenzymatic incorporation of glucose and galactose into brain cytoskeletal proteins in vitro, *Neurochem. Int.* 21 (1992) 177–183.
- [35] M. Brownlee, Advanced protein glycosylation in diabetes and aging, *Annu. Rev. Med.* 46 (1995) 223–234.
- [36] M. Brownlee, S. Pongor, A. Cerami, Covalent attachment of soluble proteins by nonenzymatically glycosylated collagen: role in the in situ formation of immune complexes, *J. Exp. Med.* 158 (1983) 1739–1744.
- [37] M. Brownlee, H. Vlassara, A. Cerami, Nonenzymatic glycosylation products on collagen covalently trap low-density lipoprotein, *Diabetes* 34 (1985) 938–941.
- [38] R. Bucala, K.J. Tracey, A. Cerami, Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes, *J. Clin. Invest.* 87 (1991) 432–438.
- [39] M.G. Buse, Hexosamines, insulin resistance, and the complications of diabetes: current status, *Am. J. Physiol. Endocrinol. Metab.* 290 (2006) E1–E8.
- [40] P. Cacoub, C. Renou, E. Rosenthal, P. Cohen, I. Louri, V. Loustaud-Ratti, A.-M. Yamamoto, A.-C. Camproux, P. Hausfater, L. Musset, P. Veyssier, G. Raguin, J.-C. Piette, GERMIVIC, Extrahepatic manifestations associated with hepatitis C virus infection: a prospective multicenter study of 321 patients, *Medicine* 79 (2000) 47–56.
- [41] D. Cai, D.P. McEwan, J.R. Martens, E. Meyhofer, K.J. Verhey, Single molecule imaging reveals differences in microtubule track selection between kinesin motors, *PLoS Biol.* 7 (2009) 1–14.
- [42] A.-V. Cantero, M. Portero-Otín, V. Ayala, N. Auge, M. Sanson, M. Elbaz, J.-C. Thiers, R. Pamplona, R. Salvayre, A. Nègre-Salvayre, Methylglyoxal induces advanced glycation end product (AGEs) formation and dysfunction of PDGF receptor-β: implications for diabetic atherosclerosis, *FASEB J.* 21 (2007) 3096–3106.
- [43] M. Capasso, C.M. Caporale, F. Pomilio, P. Gandolfi, A. Lugaesi, A. Uncini, Acute motor conduction block neuropathy: another Guillain-Barré variant, *Neurology* 61 (2003) 617–622.
- [44] M. Carly, R. Goodbody, M. Schröder, J. Stack, P.N. Moynagh, A.G. Bowie, The human adaptor SARM negatively regulates adaptor protein TRIF-dependent toll-like receptor signaling, *Nat. Immunol.* 7 (2006) 1074–1081.
- [45] G. Cavaletti, Chemotherapy-induced peripheral neurotoxicity (CIPN): what we need and what we know, *J. Peripher. Nerv. Syst.* 19 (2014) 66–76.
- [46] G. Cavaletti, E. Cavaletti, P. Montagnani, N. Oggioni, O. De Negri, G. Tredici, Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat, *Neurotoxicology* 18 (1997) 137–145.
- [47] CDC, National diabetes statistics report: Estimates of diabetes and its burden in the United States, 2014. U.S. Department of Health and Human Services, Atlanta, GA, (2014).

- [48] D. Chad, K. Pariser, W.G. Bradley, L.S. Adelman, V.W. Pinn, The pathogenesis of cryoglobulinemic neuropathy, *Neurology* 32 (1982) 725–729.
- [49] C.B. Chan, D. De Leo, J.W. Joseph, T.S. McQuaid, X.F. Ha, F. Xu, R.G. Tsushima, P.S. Pennefather, A.M.G. Salapatek, M.B. Wheeler, Increased uncoupling protein-2 levels in β -cells are associated with impaired glucose-stimulated insulin secretion: mechanism of action, *Diabetes* 50 (2001) 1302–1310.
- [50] C.B. Chan, P.E. MacDonald, M.C. Saleh, D.C. Johns, E. Marbán, M.B. Wheeler, Overexpression of uncoupling protein 2 inhibits glucose-stimulated insulin secretion from rat islets, *Diabetes* 48 (1999) 1482–1486.
- [51] G. Charnogursky, H. Lee, N. Lopez, Diabetic neuropathy, in: J. Biller, J.M. Ferro (Eds.), *Handbook of Clinical Neurology*, vol. 120, Elsevier, 2014, pp. 773–785.
- [52] M.-P. Chaunu, H. Ratinahirana, M. Raphael, D. Hénin, C. Lepot, F. Brun-Vezinet, J.-M. Léger, P. Brunet, J.-J. Hauw, The spectrum of changes on 20 nerve biopsies in patients with HIV infection, *Muscle Nerve* 12 (1989) 452–459.
- [53] C. Cheng, K. Tsuneyama, R. Kominami, H. Shinohara, S. Sakurai, H. Yonekura, T. Watanabe, Y. Takano, H. Yamamoto, Y. Yamamoto, Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs, *Mod. Pathol.* 18 (2005) 1385–1396.
- [54] H.T. Cheng, J.R. Dauch, J.M. Hayes, Y. Hong, E.L. Feldman, Nerve growth factor mediates mechanical allodynia in a mouse model of type 2 diabetes, *J. Neuropathol. Exp. Neurol.* 68 (2009) 1229–1243.
- [55] S.K.R. Chowdhury, D.R. Smith, A. Saleh, J. Schapansky, A. Marquez, S. Gomes, E. Akude, D. Morrow, N.A. Calcutt, P. Fernyhough, Impaired adenosine monophosphate-activated protein kinase signalling in dorsal root ganglia neurons is linked to mitochondrial dysfunction and peripheral neuropathy in diabetes, *Brain* 135 (2012) 1751–1766.
- [56] S.K.R. Chowdhury, E. Zherebitskaya, D.R. Smith, E. Akude, S. Chattopadhyay, C.G. Jolival, N.A. Calcutt, P. Fernyhough, Mitochondrial respiratory chain dysfunction in dorsal root ganglia of streptozotocin-induced diabetic rats and its correction by insulin treatment, *Diabetes* 59 (2010) 1082–1091.
- [57] M.S. Cohen, A.K. Ghosh, H.J. Kim, N.L. Jeon, S.R. Jaffrey, Chemical genetic-mediated spatial regulation of protein expression in neurons reveals an axonal function for Wld^s, *Chem. Biol.* 19 (2012) 179–187.
- [58] S. Cohen, R. Levi-Montalcini, A nerve growth-stimulating factor isolated from snake venom, *Proc. Natl. Acad. Sci.* 42 (1956) 571–574.
- [59] S. Cohen, R. Levi-Montalcini, Purification and properties of a nerve growth-promoting factor isolated from mouse sarcoma 180, *Cancer Res.* 17 (1957) 15–20.
- [60] S. Cohen, R. Levi-Montalcini, V. Hamburger, A nerve growth-stimulating factor isolated from sarcomas 37 and 180, *Proc. Natl. Acad. Sci.* 40 (1954) 1014–1018.
- [61] M. Coleman, Axon degeneration mechanisms: commonality amid diversity, *Nat. Rev. Neurosci.* 6 (2005) 889–898.
- [62] H. Colognato, C. French-Constant, M.L. Feltri, Human diseases reveal novel roles for neural laminins, *Trends Neurosci.* 28 (2005) 480–486.
- [63] F.I. Comer, G.W. Hart, Reciprocity between O-GlcNAc and O-phosphate on the carboxy terminal domain of RNA polymerase II, *Biochemistry* 40 (2001) 7845–7852.
- [64] L. Conforti, J. Gilley, M.P. Coleman, Wallerian degeneration: an emerging axon death pathway linking injury and disease, *Nat. Rev. Neurosci.* 15 (2014) 394–409.
- [65] K.A. Conklin, Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness, *Integr. Cancer Ther.* 3 (2004) 294–300.
- [66] L. Conti, L. Fantuzzi, M. Del Cornò, F. Belardelli, S. Gessani, Immunomodulatory effects of the HIV-1 gp120 protein on antigen presenting cells: implications for AIDS pathogenesis, *Immunobiology* 209 (2004) 99–115.
- [67] D.R. Cornblath, J.C. McArthur, Predominantly sensory neuropathy in patients with AIDS and AIDS-related complex, *Neurology* 38 (1988) 794–796.
- [68] H.C.F. Côté, Z.L. Brumme, K.J.P. Craib, M. Math, C.S. Alexander, B. Wynhoven, L. Ting, H. Wong, M. Harris, P.R. Harrigan, M.V. O'Shaughnessy, J.S.G. Montaner, Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients, *N. Engl. J. Med.* 346 (2002) 811–820.
- [69] N.A. Cullum, J. Mahon, K. Stringer, W.G. McLean, Glycation of rat sciatic nerve tubulin in experimental diabetes mellitus, *Diabetologia* 34 (1991) 387–389.
- [70] A. Cumaoglu, G. Ozansoy, A.M. Irat, A. Aricioglu, Ç. Karasu, N. Ari, Effect of long term, non cholesterol lowering dose of fluvastatin treatment on oxidative stress in brain and peripheral tissues of streptozotocin-diabetic rats, *Eur. J. Pharmacol.* 654 (2011) 80–85.
- [71] M.C. Dalakas, Peripheral neuropathy and antiretroviral drugs, *J. Peripher. Nerv. Syst.* 6 (2001) 14–20.
- [72] M.C. Dalakas, C. Semino-Mora, M. Leon-Monzon, Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2'3'-dideoxycytidine (ddC), *Lab. Invest.* 81 (2001) 1537–1544.
- [73] N. Das Evcimen, G.L. King, The role of protein kinase C activation and the vascular complications of diabetes, *Pharmacol. Res.* 55 (2007) 498–510.
- [74] S. de la Monte, D.H. Gabuzda, D.D. Ho, R.H. Brown Jr., E.T. Hedley-Whyte, R.T. Schooley, M.S. Hirsch, A.K. Bhan, Peripheral neuropathy in the acquired immunodeficiency syndrome, *Ann. Neurol.* 23 (1988) 485–492.
- [75] J. Descoeur, V. Pereira, A. Pizzoccaro, A. Francois, B. Ling, V. Maffre, B. Couette, J. Busserolles, C. Courteix, J. Noël, M. Lazdunski, A. Eschalier, N. Authier, E. Bourinet, Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors, *EMBO Mol. Med.* 3 (2011) 266–278.
- [76] J.J. Devaux, M. Odaka, N. Yuki, Nodal proteins are target antigens in Guillain-Barré syndrome, *J. Peripher. Nerv. Syst.* 17 (2012) 62–71.
- [77] L. Di Cesare Mannelli, M. Zanardelli, P. Failli, C. Ghelardini, Oxaliplatin-induced neuropathy: oxidative stress as pathological mechanism. Protective effect of silibinin, *J. Pain* 13 (2012) 276–284.
- [78] A.G. Dimitrov, N.A. Dimitrova, A possible link of oxaliplatin-induced neuropathy with potassium channel deficit, *Muscle Nerve* 45 (2012) 403–411.
- [79] Y. Ding, A. Kantarci, H. Hasturk, P.C. Trackman, A. Malabanan, T.E. Van Dyke, Activation of RAGE induces elevated O₂^{•−} generation by mononuclear phagocytes in diabetes, *J. Leukocyte Biol.* 81 (2007) 520–527.
- [80] X. Du, T. Matsumura, D. Edelstein, L. Rossetti, Z. Zsengeller, C. Szabó, M. Brownlee, Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells, *J. Clin. Invest.* 112 (2003) 1049–1057.
- [81] X.-L. Du, D. Edelstein, L. Rossetti, I.G. Fantus, H. Goldberg, F. Ziyadeh, J. Wu, M. Brownlee, Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation, *Proc. Natl. Acad. Sci.* 97 (2000) 12222–12226.
- [82] X.L. Du, D. Edelstein, S. Dimmeler, Q. Ju, C. Sui, M. Brownlee, Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site, *J. Clin. Invest.* 108 (2001) 1341–1348.
- [83] S. Dunn, E.E. Morrison, T.B. Liverpool, C. Molina-Paris, R.A. Cross, M.C. Alonso, M. Peckham, Differential trafficking of Kif5c on tyrosinated and detyrosinated microtubules in live cells, *J. Cell Sci.* 121 (2008) 1085–1095.
- [84] B. Duran-Jimenez, D. Dobler, S. Moffatt, N. Rabbani, C.H. Streuli, P.J. Thornalley, D.R. Tomlinson, N.J. Gardiner, Advanced glycation end products in extracellular matrix proteins contribute to the failure of sensory nerve regeneration in diabetes, *Diabetes* 58 (2009) 2893–2903.
- [85] K.S. Echtay, E.W. Inkler, K. Frischmuth, M. Klingenberg, Uncoupling proteins 2 and 3 are highly active H⁺ transporters and highly nucleotide sensitive when activated by coenzyme Q (ubiquinone), *Proc. Natl. Acad. Sci.* 98 (2001) 1416–1421.
- [86] J.L. Edwards, A. Quattrini, S.I. Lentz, C. Figueroa-Romero, F. Cerri, C. Backus, Y. Hong, E.L. Feldman, Diabetes regulates mitochondrial biogenesis and fission in mouse neurons, *Diabetologia* 53 (2010) 160–169.
- [87] R.J. Ellis, D. Rosario, D.B. Clifford, J.C. McArthur, D. Simpson, T. Alexander, B.B. Gelman, F. Vaida, A. Collier, C.M. Marra, B. Ances, J.H. Atkinson, R.H. Dworkin, S. Morgello, I. Grant, CHARTER Study Group, Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER study, *Arch. Neurol.* 67 (2010) 552–558.
- [88] G. Fattovich, G. Giustina, S. Favarato, A. Ruol, Investigators of the Italian Association for the Study of the Liver, A survey of adverse events in 11 241 patients with chronic viral hepatitis treated with alpha interferon, *J. Hepatol.* 24 (1996) 38–47.
- [89] M. Federici, R. Menghini, A. Mauriello, M.L. Hribal, F. Ferrelli, D. Lauro, P. Sbraccia, L.G. Spagnoli, G. Sesti, R. Lauro, Insulin dependent activation of endothelial nitric oxide synthase is impaired by O-linked glycosylation modification of signaling proteins in human coronary endothelial cells, *Circulation* 106 (2002) 466–472.
- [90] H.J. Federoff, D. Lawrence, M. Brownlee, Nonenzymatic glycosylation of laminin and the laminin peptide CIKAVS inhibits neurite outgrowth, *Diabetes* 42 (1993) 509–513.
- [91] D. Feldman, C. Brosnan, T.D. Anderson, Ultrastructure of peripheral neuropathy induced in rabbits by 2',3'-dideoxycytidine, *Lab. Invest.* 66 (1992) 75–85.
- [92] V. Fensterl, G.C. Sen, Interferons and viral infections, *Biofactors* 35 (2009) 14–20.
- [93] P. Fernyhough, L.T. Diemel, J. Hardy, W.J. Brewster, L. Mohiuddin, D.R. Tomlinson, Human recombinant nerve growth factor replaces deficient neurotrophic support in the diabetic rat, *Eur. J. Neurosci.* 7 (1995) 1107–1110.
- [94] A. Ferri, J.R. Sanes, M.P. Coleman, J.M. Cunningham, A.C. Kato, Inhibiting axon degeneration and synapse loss attenuates apoptosis and disease progression in a mouse model of motoneuron disease, *Curr. Biol.* 13 (2003) 669–673.
- [95] C. Ferri, A.L. Zignego, S.A. Pileri, Cryoglobulins, *J. Clin. Pathol.* 55 (2002) 4–13.
- [96] J. Ferrier, V. Pereira, J. Busserolles, N. Authier, D. Balayssac, Emerging trends in understanding chemotherapy-induced peripheral neuropathy, *Curr. Pain Headache Rep.* 17 (2013) 364–372.
- [97] J.T. Finn, M. Weil, F. Archer, R. Siman, A. Srinivasan, M.C. Raff, Evidence that Wallerian degeneration and localized axon degeneration induced by local neurotrophin deprivation do not involve caspases, *J. Neurosci.* 20 (2000) 1333–1341.
- [98] S.J.L. Flatters, G.J. Bennett, Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction, *Pain* 122 (2006) 245–257.
- [99] C. Fleury, M. Neverova, S. Collins, S. Raimbault, O. Champigny, C. Levi-Meyrueis, F. Bouillaud, M.F. Seldin, R.S. Surwit, D. Ricquier, C.H. Warden, Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia, *Nat. Genet.* 15 (1997) 269–272.
- [100] S. Fujimoto, K. Amako, Guillain-Barré syndrome and *Campylobacter jejuni* infection, *Lancet* 335 (1990) 1350.
- [101] K.H. Gabbay, L.O. Merola, R.A. Field, Sorbitol pathway: presence in nerve and cord with substrate accumulation in diabetes, *Science* 151 (1966) 209–210.

- [102] S. Genuth, Insights from the diabetes control and complications trial/epidemiology of diabetes interventions and complications study on the use of intensive glycemic treatment to reduce the risk of complications of type 1 diabetes, *Endocr. Pract.* 12 (2006) 34–41.
- [103] E.B. George, J.D. Glass, J.W. Griffin, Axotomy-induced axonal degeneration is mediated by calcium influx through ion-specific channels, *J. Neurosci.* 15 (1995) 6445–6452.
- [104] J. Gerds, D.W. Summers, Y. Sasaki, A. DiAntonio, J. Milbrandt, Sarm1-mediated axon degeneration requires both SAM and TIR interactions, *J. Neurosci.* 33 (2013) 13569–13580.
- [105] J. Gilley, M.P. Coleman, Endogenous Nmnat2 is an essential survival factor for maintenance of healthy axons, *PLoS Biol.* 8 (2010) e1000300.
- [106] E. Gornstein, T.L. Schwarz, The paradox of paclitaxel neurotoxicity: mechanisms and unanswered questions, *Neuropharmacology* 76 (2014) 175–183.
- [107] D.A. Greene, S. Yagihashi, S.A. Lattimer, A.A.F. Sima, Nerve Na⁺-K⁺-ATPase, conduction, and myo-inositol in the insulin-deficient BB rat, *Am. J. Physiol.* 247 (1984) E534–E539.
- [108] E.W. Gregg, P. Sorlie, R. Paulose-Ram, Q. Gu, M.S. Eberhardt, M. Wolz, V. Burt, L. Curtin, M. Engelgau, L. Geiss, Prevalence of lower-extremity disease in the U.S. adult population ≥40 years of age with and without diabetes, *Diabetes Care* 27 (2004) 1591–1597.
- [109] J.W. Griffin, C.Y. Li, T.W. Ho, P. Xue, C. Macko, C.Y. Gao, C. Yang, M. Tian, B. Mishu, D.R. Cornblath, G.M. McKhann, A.K. Asbury, Guillain-Barré syndrome in northern China: the spectrum of neuropathological changes in clinically defined cases, *Brain* 118 (1995) 577–595.
- [110] TDCATr, Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus, *N. Engl. J. Med.* 329 (1993) 977–986.
- [111] G. Guillain, J.-A. Barré, A. Strohl, Sur un syndrome de radiculonévrite avec hyperalbuminose du liquide céphalo-rachidien sans réaction cellulaire: remarques sur les caractères cliniques et graphiques des réflexes tendineux, *Bull. Soc. Méd. Hôp. Paris* 40 (1916) 1462–1470.
- [112] H.C. Ha, L.D. Hester, S.H. Snyder, Poly(ADP-ribose) polymerase-1 dependence of stress-induced transcription factors and associated gene expression in glia, *Proc. Natl. Acad. Sci.* 99 (2002) 3270–3275.
- [113] H.C. Ha, S.H. Snyder, Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion, *Proc. Natl. Acad. Sci.* 96 (1999) 13978–13982.
- [114] C. Hafer-Macko, S.-T. Hsieh, C.Y. Li, T.W. Ho, K. Sheikh, D.R. Cornblath, G.M. McKhann, A.K. Asbury, J.W. Griffin, Acute motor axonal neuropathy: an antibody-mediated attack on axolemma, *Ann. Neurol.* 40 (1996) 635–644.
- [115] K. Hahn, B. Robinson, C. Anderson, W. Li, C.A. Pardo, S. Morgello, D. Simpson, A. Nath, Differential effects of HIV infected macrophages on dorsal root ganglia neurons and axons, *Exp. Neurol.* 210 (2008) 30–40.
- [116] G. Hajnóczky, E. Davies, M. Madesh, Calcium signaling and apoptosis, *Biochem. Biophys. Res. Commun.* 304 (2003) 445–454.
- [117] J.W. Hammond, C.-F. Huang, S. Kaech, C. Jacobson, G. Banker, K.J. Verhey, Posttranslational modifications of tubulin and the polarized transport of kinesin-1 in neurons, *Mol. Biol. Cell* 21 (2010) 572–583.
- [118] Y. Han, M.T. Smith, Pathobiology of cancer chemotherapy- induced peripheral neuropathy (CIPN), *Front. Pharmacol.* 4 (2013) 1–16.
- [119] W. Haymaker, J.W. Kernohan, The Landry-Guillain-Barré syndrome: a clinicopathologic report of fifty fata cases and a critique of the literature, *Medicine* 28 (1949) 59–141.
- [120] F. Hellal, A. Hurtado, J. Ruschel, K.C. Flynn, C.J. Laskowski, M. Umlauf, L.C. Kapitein, D. Strikis, V. Lemmon, J. Bixby, C.C. Hoogenraad, F. Bradke, Microtubule stabilization reduces scarring and causes axon regeneration after spinal cord injury, *Science* 331 (2011) 928–931.
- [121] T.W. Ho, B. Mishu, C.Y. Li, C.Y. Gao, D.R. Cornblath, J.W. Griffin, A.K. Asbury, M.J. Blaser, G.M. McKhann, Guillain-Barré syndrome in northern China: relationship to *Campylobacter jejuni* infection and anti-glycolipid antibodies, *Brain* 118 (1995) 597–605.
- [122] T.W. Ho, H.J. Willison, I. Nachamkin, C.Y. Li, J. Veitch, H. Ung, G.R. Wang, R.C. Liu, D.R. Cornblath, A.K. Asbury, J.W. Griffin, G.M. McKhann, Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barré syndrome, *Ann. Neurol.* 45 (1999) 168–173.
- [123] A. Höke, M. Morris, N.J. Haughey, GPI-1046 protects dorsal root ganglia from gp120-induced axonal injury by modulating store-operated calcium entry, *J. Peripher. Nerv. Syst.* 14 (2009) 27–35.
- [124] B.I. Hudson, A.Z. Kalea, M. Del Mar Arriero, E. Harja, E. Boulanger, V. D'Agati, A.M. Schmidt, Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42, *J. Biol. Chem.* 283 (2008) 34457–34468.
- [125] K. Janes, T. Doyle, L. Bryant, E. Esposito, S. Cuzzocrea, J. Ryerse, G.J. Bennett, D. Salvemini, Bioenergetic deficits in peripheral nerve sensory axons during chemotherapy-induced neuropathic pain resulting from peroxynitrite-mediated post-translational nitration of mitochondrial superoxide dismutase, *Pain* 154 (2013) 2432–2440.
- [126] Y. Jiang, C. Guo, M.R. Vasko, M.R. Kelley, Implications of apurinic/apyrimidinic endonuclease in reactive oxygen signaling response after cisplatin treatment of dorsal root ganglion neurons, *Cancer Res.* 68 (2008) 6425–6434.
- [127] G. Jones, Y. Zhu, C. Silva, S. Tsutsui, C.A. Pardo, O.T. Keppler, J.C. McArthur, C. Power, Peripheral nerve-derived HIV-1 is predominantly CCR5-dependent and causes neuronal degeneration and neuroinflammation, *Virology* 334 (2005) 178–193.
- [128] M.A. Jordan, L. Wilson, Microtubules as a target for anticancer drugs, *Nat. Rev. Cancer* 4 (2004) 253–265.
- [129] J.K. Juranek, M.S. Geddis, R. Rosario, A.M. Schmidt, Impaired slow axonal transport in diabetic peripheral nerve is independent of RAGE, *Eur. J. Neurosci.* 38 (2013) 3159–3168.
- [130] T.N. Kakuda, Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity, *Clin. Ther.* 22 (2000) 685–708.
- [131] P.R. Kamerman, P.J. Moss, J. Weber, V.C.J. Wallace, A.S.C. Rice, W. Huang, Pathogenesis of HIV-associated sensory neuropathy: evidence from in vivo and in vitro experimental models, *J. Peripher. Nerv. Syst.* 17 (2012) 19–31.
- [132] S. Keilbaugh, G.A. Hobbs, M.V. Simpson, Effect of 2',3'-dideoxycytidine on oxidative phosphorylation in the PC2 cell, a neuronal model, *Biochem. Pharmacol.* 53 (1997) 1485–1492.
- [133] S.C. Keswani, C.A. Pardo, C.L. Cherry, A. Hoke, J.C. McArthur, HIV-associated sensory neuropathies, *AIDS* 16 (2002) 2105–2117.
- [134] S.C. Keswani, M. Polley, C.A. Pardo, J.W. Griffin, J.C. McArthur, A. Hoke, Schwann cell chemokine receptors mediate HIV-1 gp120 toxicity to sensory neurons, *Ann. Neurol.* 54 (2003) 287–296.
- [135] J.F. Kidd, M.F. Pilkington, M.J. Schell, K.E. Fogarty, J.N. Skepper, C.W. Taylor, P. Thorn, Paclitaxel affects cytosolic calcium signals by opening the mitochondrial permeability transition pore, *J. Biol. Chem.* 277 (2002) 6504–6510.
- [136] Y. Kim, P. Zhou, L. Qian, J.-Z. Chuang, J. Lee, C. Li, C. Iadecola, C. Nathan, A. Ding, MyD88-5 links mitochondria, microtubules and JNK3 in neurons and regulates neuronal survival, *J. Exp. Med.* 204 (2007) 2063–2074.
- [137] M. Kirstein, C. Aston, R. Hinz, H. Vlassara, Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins, *J. Clin. Invest.* 90 (1992) 439–446.
- [138] N. Kokubun, M. Nishibayashi, A. Uncini, M. Odaka, K. Hirata, N. Yuki, Conduction block in acute motor axonal neuropathy, *Brain* 133 (2010) 2897–2908.
- [139] Y. Konishi, M. Setou, Tubulin tyrosination navigates the kinesin-1 motor domain to axons, *Nat. Neurosci.* 12 (2009) 559–567.
- [140] S. Kuwabara, N. Yuki, Axonal Guillain-Barré syndrome: concepts and controversies, *Lancet Neurol.* 12 (2013) 1180–1188.
- [141] S. Kuwabara, N. Yuki, M. Koga, T. Hattori, D. Matsuura, M. Miyake, M. Noda, IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barré syndrome, *Ann. Neurol.* 44 (1998) 202–208.
- [142] T.H. Landowski, C.J. Megli, K.D. Nullmeyer, R.M. Lynch, R.T. Dorr, Mitochondrial-mediated dysregulation of Ca²⁺ is a critical determinant of velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines, *Cancer Res.* 65 (2005) 2836–2838.
- [143] D. Lavanchy, Evolving epidemiology of hepatitis C virus, *Clin. Microbiol. Infect.* 17 (2011) 107–115.
- [144] H.C. Lehmann, W. Chen, J. Borzan, J.L. Mankowski, A. Höke, Mitochondrial dysfunction in distal axons contributes to human immunodeficiency virus sensory neuropathy, *Ann. Neurol.* 69 (2011) 100–110.
- [145] G.M. Leininger, C. Backus, A.M. Sastry, Y.-B. Yi, C.-W. Wang, E.L. Feldman, Mitochondria in DRG neurons undergo hyperglycemic mediated injury through Bim-Bax and the fission protein Drp1, *Neurobiol. Dis.* 23 (2006) 11–22.
- [146] R. Levi-Montalcini, Effects of mouse tumor transplantation on the nervous system, *Ann. N. Y. Acad. Sci.* 55 (1952) 330–344.
- [147] R. Levi-Montalcini, S. Cohen, In vitro and in vivo effects of a nerve growth-stimulating agent isolated from snake venom, *Proc. Natl. Acad. Sci.* 42 (1956) 695–699.
- [148] Q.-H. Liu, D.A. Williams, C. McManus, F. Baribaud, R.W. Doms, D. Schols, E. De Clercq, M.I. Kotlikoff, R.G. Collman, B.D. Freedman, HIV-1 gp120 and chemokines activate ion channels in primary macrophages through CCR5 and CXCR4 stimulation, *Proc. Natl. Acad. Sci.* 97 (2000) 4832–4837.
- [149] T.E. Lloyd, J. Machamer, K. O'Hara, J.H. Kim, S.E. Collins, M.Y. Wong, B. Sahlin, W. Imlach, Y. Yang, E.S. Levitan, B.D. McCabe, A.L. Kolodkin, The p150(Glued) CAP-Gly domain regulates initiation of retrograde transport at synaptic termini, *Neuron* 74 (2012) 344–360.
- [150] C. Lu, J.C. He, W. Cai, H. Liu, L. Zhu, H. Vlassara, Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells, *Proc. Natl. Acad. Sci.* 101 (2004) 11767–11772.
- [151] E.R. Lunn, V.H. Perry, M.C. Brown, H. Rosen, S. Gordon, Absence of Wallerian degeneration does not hinder regeneration in peripheral nerve, *Eur. J. Neurosci.* 1 (1989) 27–33.
- [152] M.F. Lyon, B.W. Ogunkolade, M.C. Brown, D.J. Atherton, V.H. Perry, A gene affecting Wallerian nerve degeneration maps distally on mouse chromosome 4, *Proc. Natl. Acad. Sci.* 90 (1993) 9717–9720.
- [153] M. Ma, T.A. Ferguson, K.M. Schoch, J. Li, Y. Qian, F.S. Shofer, K.E. Saatman, R.W. Neumar, Calpains mediate axonal cytoskeleton disintegration during Wallerian degeneration, *Neurobiol. Dis.* 56 (2013) 34–46.
- [154] T.G.A. Mack, M. Reiner, B. Beirowski, W. Mi, M. Emanuelli, D. Wagner, D. Thomson, T. Gillingwater, F.A. Court, L. Conforti, F.S. Fernando, A. Tarlton, C. Andresen, K. Addicks, G. Magni, R.R. Ribchester, V.H. Perry, M.P. Coleman, Wallerian degeneration of injured axons and synapses is delayed by a Ube4b/Nmnat chimeric gene, *Nat. Neurosci.* 4 (2001) 1199–1206.
- [155] L.C. Maillard, Action des acides aminés sur les sêres: formation des mészanoïdines par voie mészodique, *C. R. Acad. Sci.* 154 (1912) 66–68.

- [156] G. Majno, M.L. Karnovsky, A biochemical and morphologic study of myelination and demyelination: II. Lipogenesis in vitro by rat nerves following transection, *J. Exp. Med.* 108 (1958) 197–214.
- [157] Y. Mao, FORMIN a link between kinetochores and microtubule ends, *Trends Cell Biol.* 21 (2011) 625–629.
- [158] J.L. Martin, C.E. Brown, N. Matthews-Davis, J.E. Reardon, Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis, *Antimicrob. Agents Chemother.* 38 (1994) 2743–2749.
- [159] J.C. McArthur, B.J. Brew, A. Nath, Neurological complications of HIV infection, *Lancet Neurol.* 4 (2005) 543–555.
- [160] E.S. McDonald, K.R. Randon, A. Knight, A.J. Windebank, Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity, *Neurobiol. Dis.* 18 (2005) 305–313.
- [161] E.S. McDonald, A.J. Windebank, Cisplatin-induced apoptosis of DRG neurons involves bax redistribution and cytochrome c release but not fas receptor signaling, *Neurobiol. Dis.* 9 (2002) 220–233.
- [162] G.M. McKhann, D.R. Cornblath, J.W. Griffin, T.W. Ho, C.Y. Li, Z. Jiang, H.S. Wu, G. Zhaori, Y. Liu, L.P. Joo, T.C. Liu, C.Y. Gao, J.Y. Mao, M.J. Blaser, B. Mishu, A.K. Asbury, Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China, *Ann. Neurol.* 33 (1993) 333–342.
- [163] W.G. McLean, The role of the axonal cytoskeleton in diabetic neuropathy, *Neurochem. Res.* 22 (1997) 951–956.
- [164] R. Medori, L. Autilio-Gambetti, S. Monaco, P. Gambetti, Experimental diabetic neuropathy: impairment of slow transport with changes in axon cross-sectional area, *Proc. Natl. Acad. Sci.* 82 (1985) 7716–7720.
- [165] G. Melli, S.C. Keswani, A. Fischer, W. Chen, A. Höke, Spatially distinct and functionally independent mechanisms of axonal degeneration in a model of HIV-associated sensory neuropathy, *Brain* 129 (2006) 1330–1338.
- [166] C. Meregalli, A. Canta, V.A. Carozzi, A. Chiorazzi, N. Oggioni, A. Gilardini, C. Ceresa, F. Avezza, L. Crippa, P. Marmioli, G. Cavaletti, Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats, *Eur. J. Pain* 14 (2010) 343–350.
- [167] C. Meregalli, A. Chiorazzi, V. Carozzi, A. Canta, B. Sala, M. Colombo, N. Oggioni, C. Ceresa, D. Foudah, F. La Russa, M. Miloso, G. Nicolini, P. Marmioli, D.L.H. Bennett, G. Cavaletti, Evaluation of tubulin polymerization and chronic inhibition of proteasome as cytotoxicity mechanisms in bortezomib-induced peripheral neuropathy, *Cell Cycle* 13 (2014) 612–621.
- [168] D. Metodiowa, C. Koška, Reactive oxygen species and reactive nitrogen species: relevance to cyto(neuro) toxic events and neurologic disorders. An overview, *Neurotox. Res.* 1 (1999) 197–233.
- [169] G. Meyer zu Horste, T.A. Miesbach, J.L. Muller, R. Fledrich, R.M. Stassart, B.C. Kieseier, M.P. Coleman, M.W. Sereda, The Wld^S transgene reduces axon loss in a Charcot–Marie–Tooth disease 1A rat model and nicotinamide delays post-traumatic axonal degeneration, *Neurobiol. Dis.* 42 (2011) 1–8.
- [170] B.R. Miller, C. Press, R.W. Daniels, Y. Sasaki, J. Milbrandt, A. DiAntonio, A dual leucine kinase-dependent axon self-destruction program promotes Wallerian degeneration, *Nat. Neurosci.* 12 (2009) 387–389.
- [171] S.L. Mironov, M.V. Ivannikov, M. Johansson, [Ca²⁺]_i signaling between mitochondria and endoplasmic reticulum in neurons is regulated by microtubules: from mitochondrial permeability transition pore to Ca²⁺-induced Ca²⁺ release, *J. Biol. Chem.* 280 (2005) 715–721.
- [172] L. Mohiuddin, P. Fernyhough, D.R. Tomlinson, Reduced levels of mRNA encoding endoskeletal and growth-associated proteins in sensory ganglia in experimental diabetes, *Diabetes* 44 (1995) 25–30.
- [173] Z. Mokini, M.L. Marcovecchio, F. Chiarelli, Molecular pathology of oxidative stress in diabetic angiopathy: role of mitochondrial and cellular pathways, *Diabetes Res. Clin. Pract.* 87 (2010) 313–321.
- [174] E.A. Mullokandov, W.A. Franklin, M. Brownlee, DNA damage by the glycation products of glyceraldehyde 3-phosphate and lysine, *Diabetologia* 37 (1994) 145–149.
- [175] M.P. Murphy, How mitochondria produce reactive oxygen species, *Biochem. J.* 417 (2009) 1–13.
- [176] S. Nasu, S. Misawa, C. Nakaseko, K. Shibuya, S. Ise, Y. Sekiguchi, S. Mitsuma, S. Ohmori, Y. Iwai, M. Beppu, N. Shimizu, C. Ohwada, Y. Takeda, Y. Fujimaki, S. Kuwabara, Bortezomib-induced neuropathy: axonal membrane depolarization precedes development of neuropathy, *Clin. Neurophysiol.* 125 (2014) 381–387.
- [177] A. Naudi, M. Jove, V. Ayala, A. Cassanye, J. Serrano, H. Gonzalo, J. Boada, J. Prat, M. Portero-Otin, R. Pamplona, Cellular dysfunction in diabetes as maladaptive response to mitochondrial oxidative stress, *Exp. Diabetes Res.* 2012 (2012) 1–6.
- [178] M. Neepser, A.M. Schmidt, J. Brett, S.D. Yan, F. Wang, Y.-C.E. Pan, K. Elliston, D. Stern, A. Shaw, Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins, *J. Biol. Chem.* 267 (1992) 14998–15004.
- [179] A. Nègre-Salvayre, C. Hirtz, G. Carrera, R. Cazenave, M. Trolly, R. Salvayre, L. Pénicaud, L. Casteilla, A role for uncoupling protein-2 as a regulator of mitochondrial hydrogen peroxide generation, *FASEB J.* 11 (1997) 809–815.
- [180] R. Nemni, L. Sanvito, A. Quattrini, G. Santuccio, M. Camerlingo, N. Canal, Peripheral neuropathy in hepatitis C virus infection with and without cryoglobulinaemia, *J. Neurol. Neurosurg. Psychiatry* 74 (2003) 1267–1271.
- [181] D.G. Nicholls, R.M. Locke, Thermogenic mechanisms in brown fat, *Physiol. Rev.* 64 (1984) 1–64.
- [182] K. Nishida, S. Kuchiiwa, S. Oiso, T. Futagawa, S. Masuda, Y. Takeda, K. Yamada, Up-regulation of matrix metalloproteinase-3 in the dorsal root ganglion of rats with paclitaxel-induced neuropathy, *Cancer Sci.* 99 (2008) 1618–1625.
- [183] T. Nishikawa, D. Edelstein, X.-L. Du, T. S.-i. Yamagishi, Matsumura, Y. Kaneda, M.A. Yorek, D. Beebe, P.J. Oates, H.-P. Hammes, I. Giardino, M. Brownlee, Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage, *Nature* 404 (2000) 787–790.
- [184] K.C. O'Donnell, M.E. Vargas, Sagasti, Wld^S and PGC-1 α regulated mitochondrial transport and oxidation state after axonal injury, *J. Neurosci.* 33 (2013) 14778–14790.
- [185] I.G. Obrosova, V.R. Drel, P. Pacher, O. Illytska, Z.Q. Wang, M.J. Stevens, M.A. Yorek, Oxidative-nitrosative stress and poly(ADP-ribose) polymerase (PARP) activation in experimental diabetic neuropathy: the relation is revisited, *Diabetes* 54 (2005) 3435–3441.
- [186] K. Ogawa-Goto, N. Funamoto, T. Abe, K. Nagashima, Different ceramide compositions of gangliosides between human motor and sensory nerves, *J. Neurochem.* 55 (1990) 1486–1493.
- [187] K. Ogawa-Goto, N. Funamoto, Y. Ohta, T. Abe, K. Nagashima, Myelin gangliosides of human peripheral nervous system: an enrichment of GM1 in the motor nerve myelin isolated from cauda equina, *J. Neurochem.* 59 (1992) 1844–1849.
- [188] S.B. Oh, P.B. Tran, S.E. Gillard, R.W. Hurley, D.L. Hammond, R.J. Miller, Chemokines and glycoprotein120 produce pain hypersensitivity by directly exciting primary nociceptive neurons, *J. Neurosci.* 21 (2001) 5027–5035.
- [189] J.M. Osterloh, J. Yang, T.M. Rooney, A.N. Fox, R. Adalbert, E.H. Powell, A.E. Sheehan, M.A. Avery, R. Hackett, M.A. Logan, J.M. MacDonald, J.S. Ziegenfuss, S. Milde, Y.-J. Hou, C. Nathan, A. Ding, R.H. Brown Jr., L. Conforti, M. Coleman, M. Tessier-Lavigne, S. Züchner, M.R. Freeman, dSarm/Sarm1 is required for activation of an injury-induced axon death pathway, *Science* 337 (2012) 481–484.
- [190] M. Palta, T. LeCaire, M. Sadek-Badawi, V. Herrera, K.K. Danielson, The trajectory of IGF-1 across age and duration of type 1 diabetes, *Diabetes Metab. Res. Rev.* 30 (2014).
- [191] C. Pekiner, N.A. Cullum, J.N. Hughes, A.J. Hargreaves, J. Mahon, I.F. Casson, W.G. McLean, Glycation of brain actin in experimental diabetes, *J. Neurochem.* 61 (1993) 436–442.
- [192] V.H. Perry, M.C. Brown, J.W. Tsao, The effectiveness of the gene which slows the rate of Wallerian degeneration in C57BL/6 mice declines with age, *Eur. J. Neurosci.* 4 (1992) 1000–1002.
- [193] V.H. Perry, E.R. Lunn, M.C. Brown, S. Cahusac, S. Gordon, Evidence that the rate of Wallerian degeneration is controlled by a single autosomal dominant gene, *Eur. J. Neurosci.* 2 (1990) 408–413.
- [194] C.M. Peters, J.M. Jimenez-Andrade, B.M. Jonas, M.A. Sevcik, N.J. Koewler, J.R. Chilardi, G.Y. Wong, P.W. Mantyh, Intravenous paclitaxel in the rat induces a peripheral sensory neuropathy characterized by macrophage infiltration and injury to sensory neurons and their supporting cells, *Exp. Neurol.* 203 (2007) 42–54.
- [195] C.M. Peters, J.M. Jimenez-Andrade, M.A. Kuskowski, J.R. Chilardi, P.W. Mantyh, An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat, *Brain Res.* 1168 (2007) 46–59.
- [196] C.R. Pierson, W. Zhang, Y. Murakawa, A.A.F. Sima, Insulin deficiency rather than hyperglycemia accounts for impaired neurotrophic responses and nerve fiber regeneration in type 1 diabetic neuropathy, *J. Neuropathol. Exp. Neurol.* 62 (2003) 260–271.
- [197] J.L. Podratz, A.M. Knight, L.E. Ta, N.P. Staff, J.M. Gass, K. Genelin, A. Schlattau, L. Lathroum, A.J. Windebank, Cisplatin induced mitochondrial DNA damage in dorsal root ganglion neurons, *Neurobiol. Dis.* 41 (2011) 661–668.
- [198] F.C. Polizzi, G. Andican, E. Çetin, S. Civelek, V. Yumuk, G. Burçak, Increased DNA-glycation in type 2 diabetic patients: the effect of thiamine and pyridoxine therapy, *Exp. Clin. Endocr. Diab.* 120 (2012) 329–334.
- [199] C. Press, J. Milbrandt, Mnat delays axonal degeneration caused by mitochondrial and oxidative stress, *J. Neurosci.* 28 (2008) 4861–4871.
- [200] H. Prüss, J.M. Schwab, C. Derst, A. Görtzen, R.W. Veh, Neurofascin as target of autoantibodies in Guillain-Barré syndrome, *Brain* 134 (2011) 1–2.
- [201] M. Quartu, V.A. Carozzi, S.G. Dorsey, M.P. Serra, L. Poddighe, C. Picci, M. Boi, T. Melis, M. Del Fiocco, C. Meregalli, A. Chiorazzi, C.L. Renn, G. Cavaletti, P. Marmioli, Bortezomib treatment produces nocifensive behavior and changes in the expression of TRPV1, CGRP, and substance P in the rat DRG, spinal cord, and sciatic nerve, *Biomed. Res. Int.* 2014 (2014).
- [202] B.V. Ramana, V.V. Kumar, P.N.R. Krishna, C.S. Kumar, P.U.M. Reddy, T.N. Raju, Effect of quercetin on galactose-induced hyperglycaemic oxidative stress in hepatic and neuronal tissues of Wistar rats, *Acta Diabetol.* 43 (2006) 135–141.
- [203] K.V. Ramana, B. Friedrich, R. Tammali, M.B. West, A. Bhatnagar, S.K. Srivastava, Requirement of aldose reductase for the hyperglycemic activation of protein kinase C and formation of diacylglycerol in vascular smooth muscle cells, *Diabetes* 54 (2005) 818–829.
- [204] C.L. Renn, C.C. Leitch, S. Lessans, P. Rhee, W.C. McGuire, B.A. Smith, R.J. Traub, S.G. Dorsey, Brain-derived neurotrophic factor modulates antiretroviral-induced mechanical allodynia in the mouse, *J. Neurosci. Res.* 89 (2011) 1551–1565.
- [205] D.J. Rodi, R.W. Jones, H.J. Sangane, R.A. Holton, B.A. Wallace, L. Makowski, Screening of a library of phage-displayed peptides identifies human bcl-2 as a taxol-binding partner, *J. Mol. Biol.* 285 (1999) 197–203.
- [206] B. Romani, S. Engelbrecht, Human immunodeficiency virus type 1 Vpr: functions and molecular interactions, *J. Gen. Virol.* 90 (2009) 1795–1805.

- [207] N.R. Rosenberg, P. Portegies, M. de Visser, M. Vermeulen, Diagnostic investigation of patients with chronic polyneuropathy: evaluation of a clinical guideline, *J. Neurol. Neurosurg. Psychiatry* 71 (2001) 205–209.
- [208] S. Rousset, M.-C. Alves-Guerra, J. Mozo, B. Miroux, A.-M. Cassard-Doulcier, F. Bouillaud, D. Ricquier, The biology of mitochondrial uncoupling proteins, *Diabetes* 53 (2004) S130–S135.
- [209] G. Rudofsky, A. Schroeder, A. Schlotterer, O.E. Voron'ko, M. Schlimme, J. Tafel, B.H. Isermann, P.M. Humpert, M. Morcos, A. Bierhaus, P.P. Nawroth, A. Hamann, Functional polymorphisms of UCP2 and UCP3 are associated with a reduced prevalence of diabetic neuropathy in patients with type 1 diabetes, *Diabetes Care* 29 (2006) 89–94.
- [210] J.W. Russell, A.J. Windebank, M.A. McNiven, D.J. Brat, W.S. Brimjoin, Effect of cisplatin and ACTH_{4–9} on nerve transport in cisplatin induced neurotoxicity, *Brain Res.* 676 (1995) 258–267.
- [211] Z. Sahenk, R. Barohn, P. New, J.R. Mendell, Taxol neuropathy: electrophysiological and sural nerve biopsy findings, *Arch. Neurol.* 51 (1994) 726–729.
- [212] M. Samsam, W. Mi, C. Wessig, J. Zielasek, K.V. Toyka, M.P. Coleman, R. Martini, The Wld^s mutation delays robust loss of motor and sensory axons in a genetic model for myelin-related axonopathy, *J. Neurosci.* 23 (2003) 2833–2839.
- [213] L. Santoro, F. Manganelli, C. Briani, F. Giannini, L. Benedetti, E. Vitelli, A. Mazzeo, E. Beghi, H.P.N.S. Group, Prevalence and characteristics of peripheral neuropathy in hepatitis C virus population, *J. Neurol. Neurosurg. Psychiatry* 77 (2006) 626–629.
- [214] Y. Sasaki, J. Milbrandt, Axonal degeneration is blocked by nicotinamide mononucleotide adenyltransferase (Nmnat) protein transduction into transected axons, *J. Biol. Chem.* 285 (2010) 41211–41215.
- [215] Y. Sasaki, B.P.S. Vohra, R.H. Baloh, J. Milbrandt, Transgenic mice expressing the Nmnat1 protein manifest robust delay in axonal degeneration in vivo, *J. Neurosci.* 29 (2009) 6526–6534.
- [216] Y. Sasaki, B.P.S. Vohra, F.E. Lund, J. Milbrandt, Nicotinamide mononucleotide adenyltransferase-mediated axonal protection requires enzymatic activity but not increased levels of neuronal nicotinamide adenine dinucleotide, *J. Neurosci.* 29 (2009) 5525–5535.
- [217] A.M. Schmidt, M. Vianna, M. Gerlach, J. Brett, J. Ryan, J. Kao, C. Esposito, H. Hegarty, W. Hurley, M. Clauss, F. Wang, Y.-C.E. Pan, T.C. Tsang, D. Stern, Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface, *J. Biol. Chem.* 267 (1992) 14987–14997.
- [218] A. Scuteri, A. Galimberti, D. Maggioni, M. Ravasi, S. Pasini, G. Nicolini, M. Bossi, M. Miloso, G. Cavaletti, G. Tedricci, Role of MAPKs in platinum-induced neuronal apoptosis, *Neurotoxicology* 30 (2009) 312–319.
- [219] H. Sekido, T. Suzuki, T. Jomori, M. Takeuchi, C. Yabe-Nishimura, S. Yagihashi, Reduced cell replication and induction of apoptosis by advanced glycation end products in rat Schwann cells, *Biochem. Biophys. Res. Commun.* 320 (2004) 241–248.
- [220] J.E. Shaw, R.A. Sciree, P.Z. Zimmet, Global estimates of the prevalence of diabetes for 2010 and 2030, *Diabetes Res. Clin. Pract.* 87 (2010) 4–14.
- [221] H. Shen, K.L. Hyrc, M.P. Goldberg, Maintaining energy homeostasis is an essential component of Wld^s-mediated axon protection, *Neurobiol. Dis.* 59 (2013) 69–79.
- [222] J. Shepard, N. Waugh, P. Hewitson, Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systemic review, *Health Technol. Assess.* 4 (2000) 1–67.
- [223] J.E. Shin, B.R. Miller, E. Babetto, Y. Cho, Y. Sasaki, S. Qayum, E.V. Russler, V. Cavalli, J. Milbrandt, A. DiAntonio, SCG10 is a JNK target in the axonal degeneration pathway, *Proc. Natl. Acad. Sci.* 109 (2012) E3696–E3705.
- [224] Y.K. Shin, S.Y. Jang, H.K. Lee, J. Jung, D.J. Suh, S.-Y. Seo, H.T. Park, Pathological adaptive responses of Schwann cells to endoplasmic reticulum stress in bortezomib-induced peripheral neuropathy, *Glia* 58 (2010) 1961–1976.
- [225] V.I. Shubayev, M. Angert, J. Dolkas, W.M. Campana, K. Palenscar, R.R. Myers, TNF α -induced MMP-9 promotes macrophage recruitment into injured peripheral nerve, *Mol. Cell Neurosci.* 31 (2006) 407–415.
- [226] A.A.F. Sima, W. Zhang, K. Sugimoto, D. Henry, Z. Li, J. Wahren, G. Grunberger, C-peptide prevents and improves chronic type I diabetic polyneuropathy in the BB/Wor rat, *Diabetologia* 44 (2001) 889–897.
- [227] A.A.F. Sima, W. Zhang, G. Xu, K. Sugimoto, D. Guberski, M.A. Yorek, A comparison of diabetic polyneuropathy in type II diabetic BBZDR/Wor rats and in type I diabetic BB/Wor rats, *Diabetologia* 43 (2000) 786–793.
- [228] V.P. Skulachev, Uncoupling: new approaches to an old problem of bioenergetics, *Biochim. Biophys. Acta* 1363 (1998) 100–124.
- [229] K. Smyth, J.S. Affandi, J.C. McArthur, C. Bowtell-Harris, A.M. Mijch, K. Watson, K. Costello, I.J. Woolley, P. Price, S.L. Wesselingh, K.L. Cherry, Prevalence of and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993–2006, *HIV Med.* 8 (2007) 367–373.
- [230] K.C. Sourris, J.M. Forbes, Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy – are these receptors valid therapeutic targets, *Curr. Drug Targets* 10 (2009) 42–50.
- [231] J.A. Sprowl, G. Ciarimboli, C.S. Lancaster, H. Giovinazzo, A.A. Gibson, G. Du, L.J. Janke, G. Cavaletti, A.F. Shields, A. Sparreboom, Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2, *Proc. Natl. Acad. Sci.* 110 (2013) 11199–11204.
- [232] A.W. Stitt, C. He, H. Vlassara, Characterization of the advanced glycation end-product receptor complex in human vascular endothelial cells, *Biochem. Biophys. Res. Commun.* 256 (1999) 549–556.
- [233] P.K. Stys, S.G. Waxman, B.R. Ransom, Ionic mechanisms of anoxic injury in mammalian CNS white matter: role of Na⁺ channels and Na⁺-Ca²⁺ exchanger, *J. Neurosci.* 12 (1992) 430–439.
- [234] K. Sugimoto, Y. Nishizawa, S. Horiuchi, S. Yagihashi, Localization in human diabetic peripheral nerve of N-e-carboxymethyllysine-protein adducts, an advanced glycation endproduct, *Diabetologia* 40 (1997) 1380–1387.
- [235] K. Susuki, M.N. Rasband, K. Tohyama, K. Koibuchi, S. Okamoto, K. Funakoshi, K. Hirata, H. Baba, N. Yuki, Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers, *J. Neurosci.* 27 (2007) 3956–3967.
- [236] K. Susuki, N. Yuki, D.P. Schafer, K. Hirata, G. Zhang, K. Funakoshi, M.N. Rasband, Dysfunction of nodes of Ranvier: a mechanism for anti-ganglioside antibody-mediated neuropathies, *Exp. Neurol.* 233 (2012) 534–542.
- [237] L. Svennerholm, K. Boström, P. Fredman, B. Jungbjer, A. Lekman, J.-E. Månsson, B.-M. Rynmark, Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord, *Biochim. Biophys. Acta* 1214 (1994) 115–123.
- [238] L.E. Ta, L. Espeset, J. Podratz, A.J. Windebank, Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding, *Neurotoxicology* 27 (2006) 992–1002.
- [239] T. Takigawa, H. Yasuda, R. Kikkawa, Y. Shigeta, T. Saïda, H. Kitasato, Antibodies against GM1 ganglioside affect K⁺ and Na⁺ currents in isolated rat myelinated nerve fibers, *Ann. Neurol.* 37 (1995) 436–442.
- [240] S. Tanaka, G. Avigad, B. Brodsky, E.F. Eikenberry, Glycation induces expansion of the molecular packing of collagen, *J. Mol. Biol.* 203 (1988) 495–505.
- [241] J.I. Tembl, J.M. Ferrer, M.T. Sevilla, A. Lago, F. Mayordomo, J.J. Vilchez, Neurological complications associated with hepatitis C virus infection, *Neurology* 53 (1999) 861–864.
- [242] S. Tewari, J.M. Santos, R.A. Kowluru, Damaged mitochondrial DNA replication system and the development of diabetic retinopathy, *Antioxid. Redox. Signaling* 17 (2012) 492–504.
- [243] C. Theiss, K. Meller, Taxol impairs anterograde axonal transport of microinjected horseradish peroxidase in dorsal root ganglia neurons in vitro, *Cell Tissue Res.* 299 (2000) 213–224.
- [244] F.P. Thomas, R.E. Lovelace, X.-S. Ding, S.A. Sadiq, G.W. Petty, W.H. Sherman, N. Latov, A.P. Hays, Vasculitic neuropathy in a patient with cryoglobulinemia and anti-MAG IgM monoclonal gammopathy, *Muscle Nerve* 15 (1992) 891–898.
- [245] P.K. Thomas, R.G. Lascelles, Schwann-cell abnormalities in diabetic neuropathy, *Lancet* 285 (1965) 1355–1357.
- [246] P.J. Thornalley, Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification – a role in pathogenesis and antiproliferative chemotherapy, *Gen. Pharmacol.* 27 (1996) 565–573.
- [247] M. Tiedge, S. Lortz, J. Drinkgern, S. Lenzen, Relation between antioxidant enzyme gene expression and antioxidant defense status of insulin-producing cells, *Diabetes* 46 (1997) 1733–1742.
- [248] C. Toftagen, Patient perceptions associated with chemotherapy-induced peripheral neuropathy, *Clin. J. Oncol. Nurs.* 14 (2010) E22–E28.
- [249] J.A. Tracy, P.J.B. Dyck, The spectrum of diabetic neuropathies, *Phys. Med. Rehabil. Clin. N. Am.* 19 (2008) 1–26.
- [250] H. Tsujino, E. Kondo, T. Fukuoka, Y. Dai, A. Tokunaga, K. Miki, K. Yonenobu, T. Ochi, K. Noguchi, Activating transcription factor 3 (ATF3) induction by axotomy in sensory and motoneurons: a novel neuronal marker of nerve injury, *Mol. Cell Neurosci.* 15 (2000) 170–182.
- [251] W.R. Tyor, S.L. Wesselingh, J.W. Griffin, J.C. McArthur, D.E. Griffin, Unifying hypothesis for the pathogenesis of HIV-associated dementia complex vacuolar myelopathy and sensory neuropathy, *J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.* 9 (1995) 379–388.
- [252] G. Varbiro, B. Veres, F. Gallyas Jr., B. Sumegi, Direct effect of Taxol on free radical formation and mitochondrial permeability transition, *Free Radical Biol. Med.* 31 (2001) 548–558.
- [253] A.J. Vidal-Puig, D. Grujic, C.-Y. Zhang, T. Hagen, O. Boss, Y. Ido, A. Szczepanik, J. Wade, V. Mootha, R. Cortright, D.M. Muoio, B.B. Lowell, Energy metabolism in uncoupling protein 3 gene knockout mice, *J. Biol. Chem.* 275 (2000) 16258–16266.
- [254] A.M. Vincent, B. Calabek, L. Roberts, E.L. Feldman, Biology of diabetic neuropathy, in: G. Said, C. Krarup (Eds.), *Handbook of Clinical Neurology*, vol. 115, Elsevier, 2013, pp. 591–606.
- [255] A.M. Vincent, J.L. Edwards, L.L. McLean, Y. Hong, F. Cerri, I. Lopez, A. Quattrini, E.L. Feldman, Mitochondrial biogenesis and fission in axons in cell culture and animal models of diabetic neuropathy, *Acta Neuropathol.* 120 (2010) 477–489.
- [256] A.M. Vincent, E.L. Feldman, Control of cell survival by IGF signaling pathways, *Growth Horm. IGF Res.* 12 (2002) 193–197.
- [257] A.M. Vincent, J.A. Olzmann, M. Brownlee, W.I. Sivitz, J.W. Russell, Uncoupling proteins prevent glucose-induced neuronal oxidative stress and programmed cell death, *Diabetes* 53 (2004) 726–734.
- [258] A.M. Vincent, J.W. Russell, P. Low, E.L. Feldman, Oxidative stress in the pathogenesis of diabetic neuropathy, *Endocr. Rev.* 25 (2004) 612–628.
- [259] H. Vlassara, The AGE-receptor in the pathogenesis of diabetic complications, *Diabetes Metab. Res. Rev.* 17 (2001) 436–443.

- [260] H. Vlassara, M. Brownlee, A. Cerami, High-affinity-receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for removal of senescent macromolecules, *Proc. Natl. Acad. Sci.* 82 (1985) 5588–5592.
- [261] H. Vlassara, M. Brownlee, A. Cerami, Nonenzymatic glycosylation of peripheral nerve protein in diabetes mellitus, *Proc. Natl. Acad. Sci.* 78 (1981) 5190–5192.
- [262] H. Vlassara, M. Brownlee, A. Cerami, Novel macrophage receptor for glucose-modified proteins is distinct from previously described scavenger receptors, *J. Exp. Med.* 164 (1986) 1301–1309.
- [263] H. Vlassara, M. Brownlee, K.R. Manogue, C.A. Dinarello, A. Pasagian, Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling, *Science* 240 (1988) 1546–1548.
- [264] H. Vlassara, Y.M. Li, F. Imani, D. Wojciechowski, Z. Yang, F.-T. Liu, A. Cerami, Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex, *Mol. Med.* 1 (1995) 634–646.
- [265] J. Wahren, K. Ekberg, J. Johansson, M. Henriksson, A. Pramanik, B.-L. Johansson, R. Rigler, H. Jörnvall, Role of C-peptide in human physiology, *Am. J. Physiol. Endocrinol. Metab.* 278 (2000) E759–E768.
- [266] C.-H. Wang, B. Wang, R.-L. Wendu, H.-e. Bi, G.-F. Cao, C. Ji, Q. Jiang, J. Yao, Protective role of Wallerian degeneration slow (Wld^s) gene against retinal ganglion cell body damage in a Wallerian degeneration model, *Exp. Ther. Med.* 5 (2013) 621–625.
- [267] J. Wang, Q. Zhai, Y. Chen, E. Lin, W. Gu, M.W. McBurney, Z. He, A local mechanism mediates NAD-dependent protection of axon degeneration, *J. Cell Biol.* 170 (2005) 349–355.
- [268] M.-S. Wang, Y. Wu, D.G. Culver, J.D. Glass, The gene for slow Wallerian degeneration (Wld^s) is also protective against vincristine neuropathy, *Neurobiol. Dis.* 8 (2001) 155–161.
- [269] M.S. Wang, A.A. Davis, D.G. Culver, J.D. Glass, Wld^s mice are resistant to paclitaxel (Taxol) neuropathy, *Ann. Neurol.* 52 (2002) 442–447.
- [270] M.S. Wang, A.A. Davis, D.G. Culver, Q. Wang, J.C. Powers, J.D. Glass, Calpain inhibition protects against Taxol-induced sensory neuropathy, *Brain* 127 (2004) 671–679.
- [271] X.-M. Wang, T.J. Lehky, J.M. Brell, S.G. Dorsey, Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy, *Cytokine* 59 (2012) 3–9.
- [272] R.A. Warwick, M. Hanani, The contribution of satellite glial cells to chemotherapy-induced neuropathic pain, *Eur. J. Pain* 17 (2013) 571–580.
- [273] J.-L. Wautier, M.-P. Wautier, A.-M. Schmidt, G.M. Anderson, O. Hori, C. Zoukourian, L. Capron, O. Chappey, S.-D. Yan, J. Brett, P.-J. Guillausseau, D. Stern, Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications, *Proc. Natl. Acad. Sci.* 91 (1994) 7742–7746.
- [274] S.K. Williams, N.L. Howarth, J.J. Devenny, M.W. Bitensky, Structural and functional consequences of increased tubulin glycosylation in diabetes mellitus, *Proc. Natl. Acad. Sci.* 79 (1982) 6546–6550.
- [275] J.B. Winer, An update on Guillain-Barré syndrome, *Autoimmune Dis.* 2014 (2014) 1–6.
- [276] H. Witte, D. Neukirchen, F. Bradke, Microtubule stabilization specifies initial neuronal polarization, *J. Cell Biol.* 180 (2008) 619–632.
- [277] M.Y. Wong, C. Zhou, D. Shakiryanova, T.E. Lloyd, D.L. Deitcher, E.S. Levitan, Neuropeptide delivery to synapses by long-range vesicle circulation and sporadic capture, *Cell* 148 (2012) 1029–1038.
- [278] J. Wu, F. Zhang, M. Yan, D. Wu, Q. Yu, Y. Zhang, B. Zhou, M.W. McBurney, Q. Zhai, Wld^s enhances insulin transcription and secretion via a SIRT1-dependent pathway and improves glucose homeostasis, *Diabetes* 60 (2011) 3197–3207.
- [279] W.H. Xiao, H. Zheng, G.J. Bennett, Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with neuropathy induced by paclitaxel, *Neuroscience* 203 (2012) 194–196.
- [280] W.H. Xiao, H. Zheng, F.Y. Zheng, R. Nuydens, T.F. Meert, G.J. Bennett, Mitochondrial abnormality in sensory but not motor axons in paclitaxel-evoked painful peripheral neuropathy in the rat, *Neuroscience* 199 (2011) 461–469.
- [281] X. Xiong, Y. Hao, K. Sun, J. Li, X. Li, B. Mishra, P. Soppina, C. Wu, R.I. Hume, C.A. Collins The Highwire ubiquitin ligase promotes axonal degeneration by tuning levels of Nmnat protein, *PLoS Biol.*, 10, (2012), e1001440.
- [282] C. Xu, B. Bailly-Maitre, J.C. Reed, Endoplasmic reticulum stress: cell life and death decisions, *J. Clin. Invest.* 115 (2005) 2656–2664.
- [283] N. Yahata, S. Yuasa, T. Araki, Nicotinamide mononucleotide adenyltransferase expression in mitochondrial matrix delays Wallerian degeneration, *J. Neurosci.* 29 (2009) 6276–6284.
- [284] H. Yamasaki, H. Sasaki, K. Ogawa, T. Shono, S. Tamura, A. Doi, M. Sasahara, H. Kawashima, T. Nakao, H. Furuta, M. Nishi, K. Nanjo, Uncoupling protein 2 promoter polymorphism –866G/A affects peripheral nerve dysfunction in Japanese type 2 diabetic patients, *Diabetes Care* 29 (2006) 888–894.
- [285] S.D. Yan, A.M. Schmidt, G.M. Anderson, J. Zhang, J. Brett, Y.S. Zou, D. Pinsky, D. Stern, Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins, *J. Biol. Chem.* 269 (1994) 9889–9897.
- [286] J. Yang, R.M. Weimer, D. Kallop, O. Olsen, Z. Wu, N. Renier, K. Uryu, M. Tessier-Lavigne, Regulation of axon degeneration after injury and in development by the endogenous calpain inhibitor calpastatin, *Neuron* 80 (2013) 1175–1189.
- [287] X. Yang, K. Su, M.D. Roos, Q. Chang, A.J. Paterson, J.E. Kudlow, O-linkage of N-acetylglucosamine to Sp1 activation domain inhibits its transcriptional capability, *Proc. Natl. Acad. Sci.* 98 (2001) 6611–6616.
- [288] Z. Yang, Z. Makita, Y. Hori, S. Brunelle, A. Cerami, P. Sehajpal, M. Suthanthiran, H. Vlassara, Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: relationship to macrophage receptor for glucose-modified proteins, *J. Exp. Med.* 174 (1991) 515–524.
- [289] C.-H. Yeh, L. Sturgis, J. Haidacher, X.-N. Zhang, S.J. Sherwood, R.J. Bjercke, O. Juhasz, M.T. Crow, R.G. Tilton, L. Denner, Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor- κ B transcriptional activation and cytokine secretion, *Diabetes* 50 (2001) 1495–1504.
- [290] M.A. Yorek, J.A. Dunlap, B.H. Ginsberg, myo-Inositol metabolism in 41A3 neuroblastoma cells: effects of high glucose and sorbitol levels, *J. Neurochem.* 48 (1987) 53–61.
- [291] R.J. Youle, M. Karbowski, Mitochondrial fission in apoptosis, *Nat. Rev. Mol. Cell Biol.* 6 (2005) 657–663.
- [292] S. Yui, T. Sasaki, N. Araki, S. Horiuchi, M. Yamazaki, Induction of macrophage growth by advanced glycation end products of the Maillard reaction, *J. Immunol.* 152 (1994) 1943–1949.
- [293] N. Yuki, H.-P. Hartung, Guillain-Barré syndrome, *N. Eng. J. Med.* 366 (2012) 2294–2304.
- [294] N. Yuki, K. Suzuki, M. Koga, Y. Nishimoto, M. Odaka, K. Hirata, K. Taguchi, T. Miyatake, K. Furukawa, T. Kobata, M. Yamada, Carbohydrate mimicry between human ganglioside GM1 and *Campylobacter jejuni* lipooligosaccharide causes Guillain-Barré syndrome, *Proc. Natl. Acad. Sci.* 101 (2004) 11404–11409.
- [295] N. Yuki, M. Yamada, M. Koga, M. Odaka, K. Suzuki, Y. Tagawa, S. Ueda, T. Kasama, A. Ohnishi, S. Hayashi, H. Takahashi, M. Kamijo, K. Hirata, Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside, *Ann. Neurol.* 49 (2001) 712–720.
- [296] N. Yuki, H. Yoshino, S. Sato, T. Miyatake, Acute axonal polyneuropathy associated with anti-GM1 antibodies following *Campylobacter* enteritis, *Neurology* 40 (1990) 1900–1902.
- [297] Q. Zhai, J. Wang, A. Kim, Q.-H. Liu, R. Watts, E. Hooper, T. Mitchison, L. Luo, Z. He, Involvement of the ubiquitin-proteasome system in the early stages of Wallerian degeneration, *Neuron* 39 (2003) 217–225.
- [298] R.G. Zhai, Y. Cao, P.R. Hiesinger, Y. Zhou, S.Q. Mehta, K.L. Schulze, P. Verstreken, H.J. Bellen, *Drosophila* NMNAT maintains neural integrity independent of its NAD synthesis activity, *PLoS Biol.* 4 (2006) 2336–2348.
- [299] R.G. Zhai, F. Zhang, P.R. Hiesinger, Y. Cao, C.M. Haueter, H.J. Bellen, NAD synthase NMNAT acts as a chaperone to protect against neurodegeneration, *Nature* 452 (2008) 887–892.
- [300] Z. Zhang, C.W. Liew, D.E. Handy, Y. Zhang, J.E. Leopold, J. Hu, L. Guo, R.N. Kulkarni, J. Loscalzo, R.C. Stanton, High glucose inhibits glucose-6-phosphate dehydrogenase, leading to increased oxidative stress and β -cell apoptosis, *FASEB J.* 24 (2010) 1497–1505.
- [301] H. Zheng, W.H. Xiao, G.J. Bennett, Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked peripheral neuropathy, *Exp. Neurol.* 232 (2011) 154–161.
- [302] H. Zheng, W.H. Xiao, G.J. Bennett, Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy, *Exp. Neurol.* 238 (2012) 225–234.
- [303] X. Zheng, H. Ouyang, S. Liu, M. Mata, D.J. Fink, S. Hao, TNF α is involved in neuropathic pain induced by nucleoside reverse transcriptase inhibitor in rats, *Brain Behav. Immun.* 25 (2011) 1668–1676.
- [304] S.S. Zhu, Y. Ren, M. Zhang, J.Q. Cao, Q. Yang, X.Y. Li, H. Bai, L. Jiang, Q. Jiang, Z.G. He, Q. Chen, Wld^s protects against peripheral neuropathy and retinopathy in an experimental model of diabetes in mice, *Diabetologia* 54 (2011) 2440–2450.
- [305] Y. Zhu, J.M. Antony, J.A. Martinez, D.M. Glerum, V. Brussee, A. Hoke, D. Zochodne, C. Power, Didanosine causes sensory neuropathy in an HIV/AIDS animal model: impaired mitochondrial and neurotrophic factor gene expression, *Brain* 130 (2007) 2011–2023.
- [306] D.W. Zochodne, D. Levy, Nitric oxide in damage, disease and repair of the peripheral nervous system, *Cell. Mol. Biol. (Noisy-le-grand)* 51 (2005) 255–267.